

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 December 2006 (28.12.2006)

PCT

(10) International Publication Number
WO 2006/137797 A1

(51) International Patent Classification:

C07D 405/12 (2006.01) A61P 3/06 (2006.01)
A61K 31/397 (2006.01) A61P 9/10 (2006.01)
A61P 25/28 (2006.01)

(21) International Application Number:

PCT/SE2006/000766

(22) International Filing Date: 21 June 2006 (21.06.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0501464-2 22 June 2005 (22.06.2005) SE

(71) Applicant (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ALENFALK, Susanne** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **DAHLSTRÖM, Mikael** [FI/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **HUNEGNAW, Fana** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **KARLSSON, Staffan** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **STARKE, Ingemar** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE).

(74) Agent: **ASTRAZENECA**; Global Intellectual Property, S-151 85 Södertälje (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AF, AG, AI., AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(81) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL 2-AZETIDINONE DERIVATIVES AS CHOLESTEROL ABSORPTION INHIBITORS FOR THE TREATMENT OF HYPERLIPIDAEMIC CONDITIONS



(I)

(57) Abstract: Compounds of formula (I) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.



WO 2006/137797 A1

Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions

CHEMICAL COMPOUNDS VI

This invention relates to 2-azetidinone derivatives, or pharmaceutically acceptable
5 salts, solvates, solvates of such salts and prodrugs thereof. These 2-azetidinones possess
cholesterol absorption inhibitory activity and are accordingly of value in the treatment of
disease states associated with hyperlipidaemic conditions. They are therefore useful in
methods of treatment of a warm-blooded animal, such as man. The invention also relates to
processes for the manufacture of said 2-azetidinone derivatives, to pharmaceutical
10 compositions containing them and to their use in the manufacture of medicaments to inhibit
cholesterol absorption in a warm-blooded animal, such as man. A further aspect of this
invention relates to the use of the compounds of the invention in the treatment of dyslipidemic
conditions.

Atherosclerotic coronary artery disease is a major cause of death and morbidity in the
15 western world as well as a significant drain on healthcare resources. It is well-known that
hyperlipidaemic conditions associated with elevated concentrations of total cholesterol and
low density lipoprotein (LDL) cholesterol are major risk factors for cardiovascular
atherosclerotic disease (for instance "Coronary Heart Disease: Reducing the Risk; a
Worldwide View" Assman G., Carmena R. Cullen P. *et al*; Circulation 1999, 100, 1930-1938
20 and "Diabetes and Cardiovascular Disease: A Statement for Healthcare Professionals from the
American Heart Association" Grundy S, Benjamin L., Burke G., *et al*; Circulation, 1999, 100,
1134-46).

Sitosterolemia is a lipid storage disorder characterised by increased levels of sitosterol
and other plant sterols in the plasma and other tissues due to increased non-selective intestinal
25 absorption of sterols and decreased hepatic removal. Sitosterolemia can result in accelerated
atherosclerosis and other cardiovascular diseases. See WO 02/058696.

The concentration of plasma cholesterol depends on the integrated balance of
endogenous and exogenous pathways of cholesterol metabolism. In the endogenous pathway,
30 cholesterol is synthesized by the liver and extra hepatic tissues and enters the circulation as
lipoproteins or is secreted into bile. In the exogenous pathway cholesterol from dietary and
biliary sources is absorbed in the intestine and enters the circulation as component of
chylomicrons. Alteration of either pathway will affect the plasma concentration of cholesterol.

The precise mechanism by which cholesterol is absorbed from the intestine is however not clear.

A clear association between reduction of total cholesterol and (LDL) cholesterol and decreased instance of coronary artery disease has been established, and several classes of pharmaceutical agents are used to control serum cholesterol. The major options to regulate plasma cholesterol include (i) blocking the synthesis of cholesterol by agents such as HMG-CoA reductase inhibitors, for example statins such as simvastatin and fluvastatin, which also by up-regulation of LDL-receptors will promote the cholesterol removal from the plasma; (ii) blocking the bile acid reabsorption by specific agents resulting in increased bile acid excretion and synthesis of bile acids from cholesterol with agents such as bile acid binders, such as resins e.g. cholestyramine and cholestipol; and (iii) by blocking the intestinal uptake of cholesterol by selective cholesterol absorption inhibitors. High density lipoprotein (HDL) elevating agents such as fibrates and nicotinic acid analogues have also been employed.


Compounds possessing such cholesterol absorption inhibitory activity have been described, see for instance the compounds described in WO 93/02048, WO 94/17038, WO 95/08532, WO 95/26334, WO 95/35277, WO 96/16037, WO 96/19450, WO 97/16455, WO 02/50027, WO 02/50060, WO 02/50068, WO 02/50090, WO 02/66464, WO 04/000803, WO 04/000804, WO04/000805, WO04/01993, WO04/010948, WO04/043456 WO 04/043457, WO 04/081002, WO05/000353, WO05/021495, WO05/021497, WO05/033100, US 5756470, US 5767115, US 20040180860, US20040180861 and US RE37721.

The present invention is based on the discovery that certain 2-azetidinone derivatives surprisingly inhibit cholesterol absorption. Such properties are expected to be of value in the treatment of disease states associated with hyperlipidaemic conditions. The compounds of the present invention are not disclosed in any of the above applications and we have surprisingly found that the compounds of the present invention possess beneficial efficacious, metabolic and toxicological profiles that make them particularly suitable for *in vivo* administration to a warm blooded animal, such as man. In particular certain compounds of the present invention have a low degree of absorption compared to compounds of the prior art whilst retaining their ability to inhibit cholesterol absorption.

Accordingly there is provided a compound of formula (I):

A compound of formula (I):

- 3 -



5

Wherein:

$X = -CH_2-$, $-CH_2CH_2-$, $-CH_2CH_2CH_2-$;

10 $R^1 = H$, C_{1-6} alkyl, C_{3-6} cycloalkyl or aryl;

R^2 and R^3 is hydrogen, a branched or unbranched C_{1-6} alkyl, C_{3-6} cycloalkyl or aryl; wherein said C_{1-6} alkyl may be optionally substituted by one or more hydroxy, amino, guanidino, carbamoyl, carboxy, C_{1-6} alkoxy, $(C_1-C_4 \text{ alkyl})_3Si$, $N-(C_{1-6}alkyl)amino$,

15 $N,N-(C_{1-6}alkyl)_2amino$, $C_{1-6}alkylS(O)_a$ wherein a is 0-2, C_{3-6} cycloalkyl or aryl; and wherein any aryl group may be optionally substituted by one or two substituents selected from halo, hydroxy, cyano, C_{1-6} alkyl or C_{1-6} alkoxy;

R^4 is hydrogen, C_{1-6} alkyl, or aryl C_{1-6} alkyl;

wherein R^3 and R^2 may form a ring with 3-7 carbon atoms and wherein R^4 and R^2 may form a

20 ring with 2-6 carbon atoms;

R^5 is selected from hydrogen, halo, nitro, cyano, hydroxy, carboxy, carbamoyl, sulphamoyl, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkanoyloxy, $N-(C_{1-6}alkyl)amino$, $N,N-(C_{1-6}alkyl)_2amino$, $C_{1-6}alkanoylamino$, $N-(C_{1-6}alkyl)carbamoyl$,

$N,N-(C_{1-6}alkyl)_2carbamoyl$, $C_{1-6}alkylS(O)_a$ wherein a is 0 to 2, $C_{1-6}alkoxycarbonyl$,

25 $N-(C_{1-6}alkyl)sulphamoyl$ and $N,N-(C_{1-6}alkyl)_2sulphamoyl$; and wherein n is 0, 1, 2 or 3.

In this specification the term "alkyl" includes both straight and branched chain alkyl groups but references to individual alkyl groups such as "propyl" are specific for the straight chain

version only. For example, "C₁₋₆alkyl" and "C₁₋₄alkyl" include propyl, isopropyl and *t*-butyl. However, references to individual alkyl groups such as 'propyl' are specific for the straight chained version only and references to individual branched chain alkyl groups such as 'isopropyl' are specific for the branched chain version only. A similar convention applies to
 5 other radicals, for example "phenylC₁₋₆alkyl" would include benzyl, 1-phenylethyl and 2-phenylethyl. The term "halo" refers to fluoro, chloro, bromo and iodo.

Where optional substituents are chosen from "one or more" groups it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups.

10 The term "aryl" refers to a 4-10 membered aromatic mono or bicyclic ring containing 0 to 5 heteroatoms independently selected from nitrogen, oxygen or sulphur. Examples of aryls include phenyl, pyrrolyl, furanyl, imidazolyl, triazolyl, tetrazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyridyl, isoxazolyl, oxazolyl, 1,2,4 oxadiazolyl, isothiazolyl, thiazolyl, 1,2,4-triazolyl, thienyl, naphthyl, benzofuranyl, benzimidazolyl, benzthienyl,
 15 benzthiazolyl, benzisothiazolyl, benzoxazolyl, benzisoxazolyl, 1,3-benzodioxolyl, indolyl, pyridoimidazolyl, pyrimidoimidazolyl, quinolyl, isoquinolyl, quinoxalyl, quinazolinyl, phthalazinyl, cinnolinyl and naphthyridinyl. Particularly "aryl" refers to phenyl, thienyl, pyridyl, imidazolyl or indolyl. The term "aryl" includes both unsubstituted and substituted aromatic rings.

20 Examples of "C₁₋₆alkoxy" include methoxy, ethoxy and propoxy. Examples of "C₁₋₆alkylS(O)_a wherein a is 0 to 2" include methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl. Examples of "N-(C₁₋₆alkyl)amino" include methylamino and ethylamino. Examples of "N,N-(C₁₋₆alkyl)₂amino" include di-*N*-methylamino, di-(*N*-ethyl)amino and *N*-ethyl-*N*-methylamino. "C₃₋₆cycloalkyl" refers to
 25 cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

A suitable pharmaceutically acceptable salt of a compound of the invention, or other compounds disclosed herein, is, for example, an acid-addition salt of a compound of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric,
 30 trifluoroacetic, citric, acetate or maleic acid. In addition a suitable pharmaceutically acceptable salt of a compound of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a

physiologically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.

The compounds of the formula (I), or other compounds disclosed herein, may be administered in the form of a pro-drug which is broken down in the human or animal body to
5 give a compound of the formula (I). Examples of pro-drugs include *in vivo* hydrolysable esters and *in vivo* hydrolysable amides of a compound of the formula (I).

An *in vivo* hydrolysable ester of a compound of the formula (I), or other compounds disclosed herein, containing carboxy or hydroxy group is, for example, a pharmaceutically acceptable ester which is hydrolysed in the human or animal body to produce the parent acid
10 or alcohol. Suitable pharmaceutically acceptable esters for carboxy include C₁₋₆alkoxymethyl esters for example methoxymethyl, C₁₋₆alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C₃₋₈cycloalkoxycarbonyloxyC₁₋₆alkyl esters for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolen-2-onylmethyl esters for example 5-methyl-1,3-dioxolen-2-onylmethyl; and C₁₋₆alkoxycarbonyloxyethyl esters for example
15 1-methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.

An *in vivo* hydrolysable ester of a compound of the formula (I), or other compounds disclosed herein, containing a hydroxy group includes inorganic esters such as phosphate esters and α -acyloxyalkyl ethers and related compounds which as a result of the *in vivo*
20 hydrolysis of the ester breakdown to give the parent hydroxy group. Examples of α -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxy-methoxy. A selection of *in vivo* hydrolysable ester forming groups for hydroxy include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxycarbonyl (to give alkyl carbonate esters), dialkylcarbamoyl and *N*-(dialkylaminoethyl)-*N*-alkylcarbamoyl (to give
25 carbamates), dialkylaminoacetyl and carboxyacetyl. Examples of substituents on benzoyl include morpholino and piperazino linked from a ring nitrogen atom via a methylene group to the 3- or 4- position of the benzoyl ring.

A suitable value for an *in vivo* hydrolysable amide of a compound of the formula (I), or other compounds disclosed herein, containing a carboxy group is, for example, a
30 *N*-C₁₋₆alkyl or *N,N*-di-C₁₋₆alkyl amide such as *N*-methyl, *N*-ethyl, *N*-propyl, *N,N*-dimethyl, *N*-ethyl-*N*-methyl or *N,N*-diethyl amide.

Some compounds of the formula (I) may have chiral centres and/or geometric isomeric centres (E- and Z- isomers), and it is to be understood that the invention

encompasses all such optical, diastereoisomers and geometric isomers that possess cholesterol absorption inhibitory activity.


The invention relates to any and all tautomeric forms of the compounds of the formula (I) that possess cholesterol absorption inhibitory activity.

5 It is also to be understood that certain compounds of the formula (I) can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which possess cholesterol absorption inhibitory activity.

10 Preferred aspects of the invention are those which relate to the compound of formula (I) or a pharmaceutically acceptable salt thereof.


Another aspect of the present invention provides a process for preparing a compound
15 of formula (I) or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof which process (wherein variable groups are, unless otherwise specified, as defined in formula (I)) comprises of:

Process 1) reacting a compound of formula (II):



20 (II)

with a compound of formula (III):




(III)

wherein L is a displaceable group;


25 *Process 2)* reacting an acid of formula (IV):

- 7 -



(IV)


or an activated derivative thereof; with an amine of formula (V):



(V)


5

Process 3): reacting an acid of formula (VI):



(VI)

or an activated derivative thereof, with an amine of formula (VII):




(VII)

10


Process 4): reducing a compound of formula (VIII):

- 8 -



(VIII)


Process 5): reacting a compound of formula (IX):



5

(IX)

with a compound of formula (X):




(X)

10 wherein L is a displaceable group;


Process 6): reacting a compound of formula (XI):

- 9 -




(XI)

wherein L is a displaceable group; with a compound of formula (XII):



(XII)

Process 7): De-esterifying a compound of formula (XIII)



(XIII)

wherein the group C(O)OR is an ester group;

and thereafter if necessary or desirable:

- i) converting a compound of the formula (I) into another compound of the formula (I);
- 15 ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug; or
- iv) separating two or more enantiomers.

L is a displaceable group, suitable values for L are for example, a halogeno or


sulphonyloxy group, for example a chloro, bromo, methanesulphonyloxy or toluene-4-sulphonyloxy group.

C(O)OR is an ester group, suitable values for C(O)OR are methoxycarbonyl, ethoxycarbonyl, *t*-butoxycarbonyl and benzyloxycarbonyl.

5 The starting materials used in the present invention can be prepared by modifications of the routes described in EP 0 792 264 B1. Alternatively they can be prepared by the following reactions.

Process 1): Alcohols of formula (II) may be reacted with compounds of formula (III) in the presence of a base for example an inorganic base such as sodium carbonate, or an organic
10 base such as Hunigs base, in the presence of a suitable solvent such as acetonitrile, dichloromethane or tetrahydrofuran at a temperature in the range of 0°C to reflux, preferably at or near reflux.

Compounds of formula (II) may be prepared according to the following scheme:




Scheme 1

wherein pMeOBz is para methoxy benzyl.

Compounds of formula (IIb), (IIId), (IIg) and (III) are commercially available
 5 compounds, or they are known in the literature, or they are prepared by standard processes
 known in the art.

Another aspect of the present invention provides a process for preparing a compound of formula (I2)




5

(I2)

or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof which process (wherein variable groups are, unless otherwise specified, as defined in formula (I)) comprises of:


Process 1) reacting a compound of formula (II2):



10

(II2)

with a compound of formula (III):




(III)

15 wherein L is a displaceable group;


Process 2) reacting an acid of formula (IV2):

- 13 -



(IV2)


or an activated derivative thereof; with an amine of formula (V):



5


(V)

Process 3): reacting an acid of formula (VI2):



(VI2)

or an activated derivative thereof, with an amine of formula (VII):




10

(VII)


Process 4): reducing a compound of formula (VIII2):

- 14 -



(VIII2)


Process 5): reacting a compound of formula (IX2):



(IX2)

5


with a compound of formula (X):



(X)


wherein L is a displaceable group;

10 Process 6): reacting a compound of formula (XI2):




(XI2)

wherein L is a displaceable group; with a compound of formula (XII):



(XII)

Process 7): De-esterifying a compound of formula (XIII2)



(XIII2)

5

wherein the group C(O)OR is an ester group;

and thereafter if necessary or desirable:

- 10 i) converting a compound of the formula (I2) into another compound of the formula (I2);
ii) removing any protecting groups;
iii) forming a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug; or
iv) separating two or more enantiomers.

L is a displaceable group, suitable values for L are for example, a halogeno or sulphonyloxy group, for example a chloro, bromo, methanesulphonyloxy or

- 15 toluene-4-sulphonyloxy group.

C(O)OR is an ester group, suitable values for C(O)OR are methoxycarbonyl, ethoxycarbonyl, *t*-butoxycarbonyl and benzyloxycarbonyl.


The starting materials used in the present invention can be prepared by modifications of the routes described in EP 0 792 264 B1. Alternatively they can be prepared by the

- 20 following reactions.

Process 1): Alcohols of formula (II2) may be reacted with compounds of formula (III) in the presence of a base for example an inorganic base such as sodium carbonate, or an organic base such as Hunigs base, in the presence of a suitable solvent such as acetonitrile,

- dichloromethane or tetrahydrofuran at a temperature in the range of 0°C to reflux, preferably
25 at or near reflux.

Compounds of formula (II2) may be prepared according to the following scheme:




Scheme 1

wherein pMeOBz is para methoxy benzyl.


- 5 Compounds of formula (IIb), (IIId), (IIg2) and (III2) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.

A compound of formula (V) may also be reacted with a compound of formula (XIV).

- 18 -



Compounds of formula XIV may be prepared by the following route:




A compound of formula (III2) may also be reacted with a compound of formula (XIV2).


5

Compounds of formula (XIV2) may be prepared according to the following route:

- 20 -




A compound of formula (XV) may be reduced to a compound of formula (IV) or a compound of formula (XV) may be reacted with a compound of formula (V):



(XV)

A compound of formula (XV2) may be reduced to a compound of formula (IV2) or a compound of formula (XV2) may be reacted with a compound of formula (V)




(XV2)

5


Compounds of formula (XV2) may be prepared according to the following route:

10



The steps in this scheme are not restricted to the reagents, conditions or protecting groups mentioned.

Compounds of formula (XV2) may be prepared according to the following scheme:



The steps in this scheme are not restricted to the reagents, conditions or protecting groups mentioned.

For XIV and (XV), and in an analogous manner for XIV2 and (XV2) both the following applies:

Process 2) and *Process 3)*: Acids and amines may be coupled together in the presence of a suitable coupling reagent. Standard peptide coupling reagents known in the art can be employed as suitable coupling reagents, for example carbonyldiimidazole and
5 dicyclohexyl-carbodiimide, optionally in the presence of a catalyst such as dimethylaminopyridine or 4-pyrrolidinopyridine, optionally in the presence of a base for example triethylamine, pyridine, or 2,6-di-*alkyl*-pyridines such as 2,6-lutidine or 2,6-di-*tert*-butylpyridine. Suitable solvents include dimethylacetamide, dichloromethane, benzene, tetrahydrofuran and dimethylformamide. The coupling reaction may conveniently be
10 performed at a temperature in the range of -40 to 40°C.

Suitable activated acid derivatives include acid halides, for example acid chlorides, and active esters, for example pentafluorophenyl esters. The reaction of these types of compounds with amines is well known in the art, for example they may be reacted in the presence of a base, such as those described above, and in a suitable solvent, such as those
15 described above. The reaction may conveniently be performed at a temperature in the range of -40 to 40°C.

Acids of formula (IV) and (VI) may be prepared from compounds of formula (II) by reacting them with the appropriate, optionally protected, side chain using the conditions of *Process 1)*. Alternatively, acids of formula (IV) and (VI) may be prepared by a modification
20 of *Scheme I*.

Amines of formula (V) and (VII) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.

Process 4): Reduction of compounds of formula (VIII) could be performed with a hydride reagent such as sodium borohydride in a solvent such as methanol at temperatures suitable
25 between -20-40°C.

Compounds of formula (VIII) can be prepared from compounds of formula (III), by deprotecting the benzyl group and performing *Process 1*. Alternatively compound (III_k) could be debenzylated, *Process 1* could be performed and the resulting compound deprotected to reveal the ketone.

30 *Process 5)* and *Process 6)*: these compounds may be reacted together in the presence of a base for example an inorganic base such as sodium carbonate, or an organic base such as Hunigs base, in the presence of a suitable solvent such as acetonitrile, dichloromethane or tetrahydrofuran at a temperature in the range of 0°C to reflux, preferably at or near reflux.

Compounds of formula (IX) and (XI) may be prepared by an appropriate modification of *Scheme 1*.

Compounds of formula (X) and (XII) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.

5 *Process 7*): Esters of formula (XIII) may be deprotected under standard conditions such as those described below, for example a methyl or ethyl ester may be deprotected with sodium hydroxide in methanol at room temperature.

Compounds of formula (XIII) may be prepared by a modification of any of the processes described herein for the preparation of compounds of formula (I).

10 It will be appreciated that certain of the various ring substituents in the compounds of the present invention may be introduced by standard aromatic substitution reactions or generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. Such reactions and modifications include, for example, introduction of a
15 substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents and oxidation of substituents. The reagents and reaction conditions for such procedures are well known in the chemical art. Particular examples of aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as
20 aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogeno group. Particular examples of modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric
25 acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.

It will also be appreciated that in some of the reactions mentioned herein it may be necessary/desirable to protect any sensitive groups in the compounds. The instances where protection is necessary or desirable and suitable methods for protection are known to those skilled in the art. Conventional protecting groups may be used in accordance with standard
30 practice (for illustration see T.W. Green, *Protective Groups in Organic Synthesis*, John Wiley and Sons, 1999). Thus, if reactants include groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein.


A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or *t*-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection
5 conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a *t*-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid
10 as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by
15 treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.

A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl
20 group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

A suitable protecting group for a carboxy group is, for example, an esterifying group,
25 for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a *t*-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

30 The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.

The invention further provides for a compound of the formula (XVI) or hydrolysable esters or amides thereof:




(XVI)

5

wherein R⁷ is an hydroxy group or a C₁₋₄ alkoxy group. R¹, is as defined above regarding formula (I). A compound of formula (XVI) may be an intermediate to formula (I).

The invention further provides for a compound of the formula (XVI2) or hydrolysable esters
10 or amides thereof:



(XVI2)

15 wherein R⁷ is an hydroxy group or a C₁₋₃ alkoxy group. R¹ is as defined above regarding formula (I). A compound of formula (XVI2) may be an intermediate to formula (I2).

As stated hereinbefore the compounds defined in the present invention possess cholesterol absorption inhibitory activity. These properties may be assessed, using the following biological tests.

20

In vivo testing of cholesterol absorption inhibitors (A)

C57BL/6 female mice were maintained on regular chow diet and housed in individual cages to collect faeces. Mice were fasted for 3 hours and then gavaged with vehicle or compound. Half an hour later the mice were gavaged with radiolabelled cholesterol. Six hours after the ^{14}C -cholesterol gavage blood samples were taken via the tail and plasma prepared to determine how much cholesterol were absorbed. 24 hours after the gavage of ^{14}C -cholesterol the mice were bled and plasma were prepared for analysis. Faeces were collected for 24 hours to assess absorption efficiency.

In vivo testing of cholesterol absorption inhibitors (B).

C57BL/6 female mice were maintained on regular chow diet and housed in individual cages to collect faeces. Mice were fasted for 3 hours and then gavaged with vehicle or compound. One to ten hours later the mice were gavaged with radiolabelled cholesterol. Six hours after the ^{14}C -cholesterol gavage blood sample was taken via the tail and plasma prepared to determine how much cholesterol was absorbed. 24 hours after the gavage of ^{14}C -cholesterol the mice were bled and plasma analysed for radioactivity. Faeces were also collected for 24 hours to assess absorption efficiency.

References

1. E. A. Kirk, G. L. Moe, M. T. Caldwell, J. Å. Lernmark, D. L. Wilson, R. C. LeBoeuf. Hyper- and hypo-responsiveness to dietary fat and cholesterol among inbred mice: searching for level and variability genes. J. Lipid Res. 1995 36:1522-1532.
2. C. P. Carter, P. N. Howles, D. Y. Hui. Genetic variation in cholesterol absorption efficiency among inbred strains of mice. J. Nutr. 1997 127:1344-1348.
3. C. D. Jolley, J. M. Dietschy, S. D. Turley. Genetic differences in cholesterol absorption in 129/Sv and C57BL/6 mice: effect on cholesterol responsiveness. Am. J. Physiol. 1999 276:G1117-G1124.

Administration of 0.2 $\mu\text{mol/kg}$ of Example 1 gave 61% inhibition of ^{14}C -cholesterol absorption (procedure A). Administration of 0.2 $\mu\text{mol/kg}$ of Example 3 gave 67% inhibition of ^{14}C -cholesterol absorption (procedure A).

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as defined hereinbefore in association with a pharmaceutically-acceptable diluent or carrier.

The composition may be in a form suitable for oral administration, for example as a tablet or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository.

5 In general the above compositions may be prepared in a conventional manner using conventional excipients.

The compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, will normally be administered to a warm-blooded animal at a unit dose within the range of approximately 0.02-100 mg/kg, preferably 0.02 -50 mg/kg, 10 and this normally provides a therapeutically-effective dose. Preferably a daily dose in the range of 1-50 mg/kg, particularly 0.1-10 mg/kg is employed. In another aspect a daily dose in the range of 0.01-20 mg/kg is employed. In one aspect of the invention the daily dose of a compound of formula (I) is less than or equal to 100 mg. However the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, 15 and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient. A unit dose form such as a tablet or capsule will usually contain, for example 1-250 mg of active ingredient.

According to a further aspect of the present invention there is provided a compound of 20 the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as defined hereinbefore for use in a method of prophylactic or therapeutic treatment of a warm-blooded animal, such as man.

We have found that the compounds defined in the present invention, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, are 25 effective cholesterol absorption inhibitors, and accordingly have value in the treatment of disease states associated with hyperlipidaemic conditions.

Thus according to this aspect of the invention there is provided a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as defined hereinbefore for use as a medicament.

30 According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as defined hereinbefore in the manufacture of a medicament for use in the

production of a cholesterol absorption inhibitory effect in a warm-blooded animal, such as man.

According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a
5 prodrug thereof, as defined hereinbefore in the production of a cholesterol absorption inhibitory effect in a warm-blooded animal, such as man.

Herein, where the production of a cholesterol absorption inhibitory effect or a cholesterol lowering effect is stated, suitably this relates to the treatment of hyperlipidaemic conditions in a warm-blooded animal, such as man. Additionally it relates to the treatment of
10 dyslipidemic conditions and disorders such as hyperlipidaemia, hypertriglyceridemia, hyperbetalipoproteinemia (high LDL), hyperprebetalipoproteinemia (high VLDL), hyperchylomicronemia, hypolipoproteinemia, hypercholesterolemia, hyperlipoproteinemia and hypoalphalipoproteinemia (low HDL) in a warm-blooded animal, such as man. Furthermore it relates to the treatment of different clinical conditions such as atherosclerosis,
15 arteriosclerosis, arrhythmia, hyper-thrombotic conditions, vascular dysfunction, endothelial dysfunction, heart failure, coronary heart diseases, cardiovascular diseases, myocardial infarction, angina pectoris, peripheral vascular diseases, inflammation of cardiovascular tissues such as heart, valves, vasculature, arteries and veins, aneurisms, stenosis, restenosis, vascular plaques, vascular fatty streaks, leukocytes, monocytes and/or macrophage
20 infiltration, intimal thickening, medial thinning, infectious and surgical trauma and vascular thrombosis, stroke and transient ischaemic attacks in a warm-blooded animal, such as man. It also relates to the treatment of atherosclerosis, coronary heart diseases, myocardial infarction, angina pectoris, peripheral vascular diseases, stroke and transient ischaemic attacks in a warm-blooded animal, such as man.

25 The production of a cholesterol absorption inhibitory effect or a cholesterol lowering effect also relates to a method of treating and/or preventing atherosclerotic lesions, a method of preventing plaque rupture and a method of promoting lesion regression. Furthermore it relates to a method of inhibiting monocytes-macrophage accumulation in atherosclerotic lesions, a method of inhibiting expression of matrix metalloproteinases in atherosclerotic
30 lesions, a method of inhibiting the destabilization of atherosclerotic lesions, a method for preventing atherosclerotic plaque rupture and a method of treating unstable angina.

The production of a cholesterol absorption inhibitory effect or a cholesterol lowering effect also relates to a method of treating sitosterolemia.

Compounds of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof may also have value in the treatment or prevention of Alzheimer's Disease (see for example WO 02/096415). Therefore in a further aspect of the invention, there is provided a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, for use in the treatment or prevention of Alzheimer's Disease.

Compounds of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof may also have value in the treatment or prevention cholesterol associated tumors. Therefore in a further aspect of the invention, there is provided a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, for use in the treatment or prevention of cholesterol associated tumors.

Compounds of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof may also have value in the treatment or prevention of vascular inflammation (see for example WO 03/026644). Therefore in a further aspect of the invention, there is provided a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, for use in the treatment or prevention of vascular inflammation.

According to a further feature of this aspect of the invention there is provided a method for producing a cholesterol absorption inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

The cholesterol absorption inhibitory activity defined hereinbefore may be applied as a sole therapy or may involve, in addition to a compound of the invention, one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment. According to this aspect of the invention there is provided a pharmaceutical product comprising a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as defined hereinbefore and an additional cholesterol absorption inhibitory substance as defined hereinbefore and an additional hypolipidaemic agent for the conjoint treatment of hyperlipidaemia.

In another aspect of the invention, the compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, may be administered in association with cholesterol biosynthesis inhibitors, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof. Suitable cholesterol biosynthesis

5 inhibitors include HMG Co-A reductase inhibitors, squalene synthesis inhibitors and squalene epoxidase inhibitors. Suitable squalene synthesis inhibitors are e.g. squalenylamine, TAK 475 and compounds described in WO2005012284. A suitable squalene epoxidase inhibitor is NB-598.

In this aspect of the invention, the compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, may be administered in association with an HMG Co-A reductase inhibitor, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof. Suitable HMG Co-A reductase inhibitors, pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof are statins well known in the art. Particular statins are fluvastatin, lovastatin, pravastatin, simvastatin, atorvastatin, cerivastatin, bervastatin, dalvastatin, mevastatin and rosuvastatin, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof. A further particular statin is pitavastatin, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof. A particular statin is atorvastatin, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof. A more particular statin is atorvastatin calcium salt. A further particular statin is rosuvastatin, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof. A preferable particular statin is rosuvastatin calcium salt.

Therefore in an additional feature of the invention, there is provided a combination of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof and an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

Therefore in an additional feature of the invention, there is provided a method for producing a cholesterol lowering effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof in simultaneous, sequential or separate administration with an effective amount of an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in association with a pharmaceutically acceptable diluent or carrier.

According to a further aspect of the present invention there is provided a kit comprising a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

According to a further aspect of the present invention there is provided a kit comprising:

- a) a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in a first unit dosage form;
- b) an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof; in a second unit dosage form; and
- c) container means for containing said first and second dosage forms.

According to a further aspect of the present invention there is provided a kit comprising:

- a) a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, together with a pharmaceutically acceptable diluent or carrier, in a first unit dosage form;
- b) an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in a second unit dosage form; and
- c) container means for containing said first and second dosage forms.

According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the production of a cholesterol lowering effect.

According to a further aspect of the present invention there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the

simultaneous, sequential or separate administration of an effective amount of an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier to a warm-blooded animal, such as man in need of such therapeutic treatment.

5 According to an additional further aspect of the present invention there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the simultaneous, sequential or separate administration of a matrix metalloproteinase
10 inhibitor.

In another aspect of the invention, the compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, may be administered in association with an ileal bile acid (IBAT) inhibitor
15 or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof. Suitable compounds possessing IBAT inhibitory activity for use in combination with compounds of the present invention have been described, see for instance the compounds described in WO 93/16055, WO 94/18183, WO
20 94/18184, WO 94/24087, WO 96/05188, WO 96/08484, WO 96/16051, WO 97/33882, WO 98/07749, WO 98/38182, WO 98/40375, WO 98/56757, WO 99/32478, WO 99/35135, WO 99/64409, WO 99/64410, WO 00/01687, WO 00/20392, WO 00/20393, WO 00/20410, WO 00/20437, WO 00/35889, WO 01/34570, WO 00/38725, WO 00/38726, WO 00/38727, WO 00/38728, WO 00/38729, WO 00/47568, WO 00/61568, WO 01/66533, WO 01/68096, WO
25 01/68637, WO 02/08211, WO 02/50051, WO 03/018024, WO 03/040127, WO 03/043992, WO 03/061604, WO 04/020421, WO 04/076430, DE 19825804, JP 10072371, US 5070103, EP 251 315, EP 417 725, EP 489 423, EP 549 967, EP 573 848, EP 624 593, EP 624 594, EP 624 595, EP 864 582, EP 869 121 and EP 1 070 703, WO 03/020710, WO 03/022825, WO 03/022830, WO 03/022286, WO
30 03/091232, WO 03/106482, and EP 597 107.


and the contents of these patent applications are incorporated herein by reference. Particularly the named examples of these patent applications are incorporated herein by reference. More particularly claim 1 of these patent application are incorporated herein by reference.

Other suitable classes of IBAT inhibitors for use in combination with compounds of the present invention are the benzothiepines, 1,2-benzothiazepines, 1,4-benzothiazepines and 1,5-benzothiazepines. A further suitable class of IBAT inhibitors is the 1,2,5-benzothiadiazepines.

5 One particular suitable compound possessing IBAT inhibitory activity for use in combination with compounds of the present invention is (3*R*,5*R*)-3-butyl-3-ethyl-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl beta-D-glucopyranosiduronic acid (EP 864 582).

10 A further suitable compound possessing IBAT inhibitory activity for use in combination with compounds of the present invention is S-8921 (EP 597 107) and BARI-1741.

A further suitable IBAT inhibitor for use in combination with compounds of the present invention is the compound:



15

WO 99/32478

A particular IBAT inhibitor for use in combination with compounds of the present invention is selected from any one of Examples 1-120 of WO 02/50051, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and the compounds of Examples 1-120 are incorporated herein by reference. Claims 1-15 of WO 02/50051 are also
 20 incorporated herein by reference. A particular IBAT inhibitor selected from WO 02/50051 for use in combination with compounds of the present invention is selected from any one of:
 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-(*R*)-1'-phenyl-1'-[*N'*-(carboxymethyl) carbamoyl]methyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(carboxymethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)-1'-phenyl-1'-[*N'*-(2-sulphoethyl)carbamoyl]methyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 5 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(R)-1'-phenyl-1'-[*N'*-(2-sulphoethyl)carbamoyl]methyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(2-sulphoethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(2-sulphoethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 10 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(2-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(2-carboxyethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 15 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(5-carboxypentyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(2-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(2-sulphoethyl)carbamoyl]-2-fluorobenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 20 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(R)-(2-hydroxy-1-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(R)-(2-hydroxy-1-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 25 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-{*N*-[(R)- α -(*N'*-{(R)-1-[*N''*-(R)-(2-hydroxy-1-carboxyethyl)carbamoyl]-2-hydroxyethyl}carbamoyl)benzyl]carbamoylmethoxy}-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(carboxymethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 30 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(ethoxy)(methyl)phosphorylmethyl]carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-{*N*-[(*R*)- α -(*N'*-{2-[(hydroxy)(methyl)phosphoryl]ethyl} carbamoyl)benzyl]carbamoylmethoxy}-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(2-methylthio-1-

5 carboxyethyl)carbamoyl]benzyl} carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-{*N*-[(*R*)- α -(*N'*-{2-[(methyl)(ethyl)phosphoryl]ethyl} carbamoyl)-4-hydroxybenzyl]carbamoylmethoxy}-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-{*N*-[(*R*)- α -(*N'*-{2-[(methyl)(hydroxy)

10 phosphoryl]ethyl} carbamoyl)-4-hydroxybenzyl]carbamoylmethoxy}-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[(*R*)-*N'*-(2-methylsulphinyl-1-carboxyethyl)carbamoyl]benzyl} carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine; and

15 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methoxy-8-[*N*-{(R)- α -[*N'*-(2-sulphoethyl)carbamoyl]-4-hydroxybenzyl} carbamoylmethoxy]-2,3,4,5-tetrahydro-1,5-benzothiazepine;

or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

A particular IBAT inhibitor for use in combination with compounds of the present invention is selected from any one of Examples 1-44 of WO 03/020710, or a pharmaceutically

20 acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and the compounds of Examples 1-44 are incorporated herein by reference. Claims 1-10 of WO 03/020710 are also incorporated herein by reference. A particular IBAT inhibitor selected from WO 03/020710 for use in combination with compounds of the present invention is selected from any one of:

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(2-(*S*)-3-(*R*)-4-(*R*)-5-(*R*)-

25 2,3,4,5,6-pentahydroxyhexyl)carbamoyl]benzyl} carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(2-(*S*)-3-(*R*)-4-(*R*)-5-(*R*)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]benzyl} carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

30 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(2-(*S*)-1-carbamoyl-2-hydroxyethyl)carbamoyl]benzyl} carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(hydroxycarbamoyl-methyl)carbamoyl]benzyl} carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

- 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-[*N*-((*R*)- α -{*N'*-[2-(*N'*-pyrimidin-2-ylureido)ethyl]carbamoyl}benzyl)carbamoylmethoxy]-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-[*N*-((*R*)- α -{*N'*-[2-(*N'*-pyridin-2-ylureido)ethyl]carbamoyl}benzyl)carbamoylmethoxy]-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-(1-*t*-butoxycarbonylpiperidin-4-ylmethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 10 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-(2,3-dihydroxypropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-[*N*-((*R*)- α -{*N'*-[2-(3,4-dihydroxyphenyl)-2-methoxyethyl]carbamoyl}benzyl)carbamoylmethoxy]-2,3,4,5-tetrahydro-1,5-benzothiazepine
- 15 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-(2-aminoethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-(piperidin-4-ylmethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine; or
- 20 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-(2-*N,N*-dimethylaminosulphamoyl)ethyl]carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
- A particular IBAT inhibitor for use in combination with compounds of the present invention is selected from any one of Examples 1-7 of WO 03/022825, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and the compounds of Examples 1-7 are incorporated herein by reference. Claims 1-8 of WO 03/022825 are also incorporated herein by reference. A particular IBAT inhibitor selected from WO 03/022825 for use in combination with compounds of the present invention is selected from any one of:
- 30 1,1-dioxo-3(*R*)-3-butyl-3-ethyl-5-(*R*)-5-phenyl-8-[*N*-((*R*)- α -carboxybenzyl)carbamoylmethoxy]-2,3,4,5-tetrahydro-1,4-benzothiazepine;
- 1,1-dioxo-3(*S*)-3-butyl-3-ethyl-5-(*S*)-5-phenyl-8-[*N*-((*R*)- α -carboxybenzyl)carbamoylmethoxy]-2,3,4,5-tetrahydro-1,4-benzothiazepine;

1,1-dioxo-3(R)-3-butyl-3-ethyl-5-(R)-5-phenyl-8-(N-{(R)- α -[N-(carboxymethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,4-benzothiazepine;

1,1-dioxo-3(S)-3-butyl-3-ethyl-5-(S)-5-phenyl-8-(N-{(R)- α -[N-(carboxymethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,4-benzothiazepine;

5 3,5-*trans*-1,1-dioxo-3-ethyl-3-butyl-5-phenyl-7-bromo-8-(N-{(R)- α -[N-(carboxymethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,4-benzothiazepine;

3,5-*trans*-1,1-dioxo-3-(S)-3-ethyl-3-butyl-4-hydroxy-5-(S)-5-phenyl-7-bromo-8-(N-{(R)- α -[N-(carboxymethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,4-

10 benzothiazepine

3,5-*trans*-1,1-dioxo-3-(R)-3-ethyl-3-butyl-4-hydroxy-5-(R)-5-phenyl-7-bromo-8-(N-{(R)- α -[N-(carboxymethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,4-benzothiazepine;

3,5-*trans*-1,1-dioxo-3-ethyl-3-butyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N-

15 (carboxymethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,4-benzothiazepine;

3,5-*trans*-1,1-dioxo-3-ethyl-3-butyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N-(2-sulphoethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,4-benzothiazepine ammonia salt;

20 1,1-dioxo-3-(S)-3-ethyl-3-butyl-5-(S)-5-phenyl-7-methylthio-8-(N-{(R)- α -[N-(carboxymethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,4-benzothiazepine diethylamine salt; and

1,1-dioxo-3-(R)-3-ethyl-3-butyl-5-(R)-5-phenyl-7-methylthio-8-(N-{(R)- α -[N-(carboxymethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,4-

25 benzothiazepine diethylamine salt;

or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

A particular IBAT inhibitor for use in combination with compounds of the present invention is selected from any one of Examples 1-4 of WO 03/022830, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and the compounds of

30 Examples 1-4 are incorporated herein by reference. Claims 1-8 of WO 03/022830 are also incorporated herein by reference. A particular IBAT inhibitor selected from WO 03/022830 for use in combination with compounds of the present invention is selected from any one of:

1,1-dioxo-3-butyl-3-ethyl-4-hydroxy-5-phenyl-7-(*N*-{(R)- α -[*N*-(carboxymethyl)carbamoyl]benzyl}carbamoylmethylthio)-2,3,4,5-tetrahydrobenzothiepine
 1,1-dioxo-3-butyl-3-ethyl-4-hydroxy-5-phenyl-7-(*N*-{(R)- α -[*N*-(2-sulphoethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethylthio)-2,3,4,5-tetrahydrobenzothiepine ammonia salt

- 5 1,1-dioxo-3-butyl-3-ethyl-4-hydroxy-5-phenyl-7-{*N*-[α -(carboxy)-2-fluorobenzyl]carbamoylmethylthio}-2,3,4,5-tetrahydrobenzothiepine; and
 1,1-dioxo-3-butyl-3-ethyl-4-hydroxy-5-phenyl-7-{*N*-[1-(carboxy)-1-(thien-2-yl)methyl]carbamoylmethylthio}-2,3,4,5-tetrahydrobenzothiepine
 or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

- 10 A particular IBAT inhibitor for use in combination with compounds of the present invention is selected from any one of Examples 1-39 of WO 03/022286, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and the compounds of Examples 1-39 are incorporated herein by reference. Claims 1-10 of WO 03/022286 are also incorporated herein by reference. A particular IBAT inhibitor selected from WO 03/022286
 15 for use in combination with compounds of the present invention is selected from any one of:
 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((R)-1-carboxy-2-methylthio-ethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;
 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxy-2-(R)-hydroxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;
 20 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxy-2-methylpropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;
 25 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxybutyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;
 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxypropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;
 30 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxy-2-(R)-hydroxypropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-(2-sulphoethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxyethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((R)-1-carboxy-2-methylthioethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-{(S)-1-[*N*-((S)-2-hydroxy-1-carboxyethyl)carbamoyl]propyl}carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxy-2-methylpropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine; and

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-[*N*-((R)- α -carboxy-4-hydroxybenzyl)carbamoylmethoxy]-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

A particular IBAT inhibitor for use in combination with compounds of the present invention is selected from any one of Examples 1-7 of WO 03/091232, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and the compounds of Examples 1-7 are incorporated herein by reference. Claims 1-10 of WO 03/091232 are also incorporated herein by reference. A particular IBAT inhibitor selected from WO 03/091232 for use in combination with compounds of the present invention is selected from any one of:

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-[*N*-((R/S)- α -{*N*-[1-(R)-2-(S)-1-hydroxy-1-(3,4-dihydroxyphenyl)prop-2-yl]carbamoyl}-4-hydroxybenzyl)carbamoylmethoxy]-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-{*N*-[(R)- α -(*N*-{2-(S)-[*N*-(carbamoylmethyl)carbamoyl]pyrrolidin-1-ylcarbonylmethyl}carbamoyl)benzyl]carbamoylmethoxy}-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

10 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-[*N*-((R)- α -{*N*-[2-(3,4,5-trihydroxyphenyl)ethyl]carbamoyl}benzyl)carbamoylmethoxy]-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine; and

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-(2-(R)-3-(S)-4-(S)-5-(R)-3,4,5,6-tetrahydroxytetrahydropyran-2-ylmethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof. Further suitable compounds possessing IBAT inhibitory for use in combination with compounds of the present invention are disclosed in WO 03/106482

Suitable IBAT inhibitors having the above structure for use in combination with compounds of the present invention are selected from any one of:

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-((S)-1-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-((S)-1-carboxypropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

25 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-((S)-1-carboxybutyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-((S)-1-carboxy-2-methylpropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

30 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-((S)-1-carboxy-2-methylbutyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-((S)-1-carboxy-3-methylbutyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-((S)-1-carboxy-2-

- hydroxypropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxy-2-mesyloethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 5 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxy-3-methylsulphonylpropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxy-3-mesylopropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 10 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxyethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxybutyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 15 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxy-2-methylpropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxy-2-methylbutyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 20 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxy-3-methylbutyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxy-2-hydroxyethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 25 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxy-2-hydroxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 30 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxy-2-methylthioethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxy-2-methylsulphinylethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxy-2-mesyloethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxy-2-methoxyethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

10 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxy-3-methylthiopropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxy-3-methylsulphonylpropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-

15 1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxy-3-mesylpropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine; or

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(*R*)- α -[*N'*-((*S*)-1-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine.

or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

25 Further suitable IBAT inhibitors for use in combination with compounds of the present invention are those disclosed in WO 04/076430.

In a particular aspect of the invention an IBAT inhibitor or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof is an IBAT inhibitor or a pharmaceutically acceptable salt thereof.

30 Therefore in an additional feature of the invention, there is provided a combination of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof and an IBAT inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

Therefore in an additional feature of the invention, there is provided a method for producing a cholesterol lowering effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt
5 or a prodrug thereof in simultaneous, sequential or separate administration with an effective amount of an IBAT inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (I), or a pharmaceutically acceptable
10 salt, solvate, solvate of such a salt or a prodrug thereof, and an IBAT inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in association with a pharmaceutically acceptable diluent or carrier.

According to a further aspect of the present invention there is provided a kit comprising a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate
15 of such a salt or a prodrug thereof, and an IBAT inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

According to a further aspect of the present invention there is provided a kit comprising:

- a) a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a
20 salt or a prodrug thereof, in a first unit dosage form;
- b) an IBAT inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof; in a second unit dosage form; and
- c) container means for containing said first and second dosage forms.

According to a further aspect of the present invention there is provided a kit
25 comprising:

- a) a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, together with a pharmaceutically acceptable diluent or carrier, in a first unit dosage form;
- b) an IBAT inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a
30 prodrug thereof, in a second unit dosage form; and
- c) container means for containing said first and second dosage forms.

According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a

prodrug thereof, and an IBAT inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the production of a cholesterol lowering effect in a warm-blooded animal, such as man.

According to a further aspect of the present invention there is provided a combination
5 treatment comprising the administration of an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the simultaneous, sequential or separate administration of an effective amount of an IBAT
inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug
10 thereof, optionally together with a pharmaceutically acceptable diluent or carrier to a warm-blooded animal, such as man in need of such therapeutic treatment.

According to a further aspect of the present invention there is provided a combination
treatment comprising the administration of an effective amount of a compound of the formula
15 (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the simultaneous, sequential or separate administration of an effective amount of an IBAT
inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug
thereof, optionally together with a pharmaceutically acceptable diluent or carrier to a warm-
20 blooded animal, such as man in need of such therapeutic treatment.

In another aspect of the invention, the compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, may be administered in association with a PPAR alpha and/or gamma and/or delta agonist, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof. Suitable PPAR alpha
25 and/or gamma and/or delta agonists, pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof are well known in the art. These include the compounds described in WO 01/12187, WO 01/12612, WO 99/62870, WO 99/62872, WO 99/62871, WO 98/57941, WO 01/40170, WO 01/40172, WO 02/085844, WO 02/096863, WO03/051821, WO03/051822, WO03/051826, WO 04/000790, WO04/000295, WO04/000294,
30 PCT/GB03/02584, PCT/GB03/02591, PCT/GB03/02598, J Med Chem, 1996, 39, 665, Expert Opinion on Therapeutic Patents, 10 (5), 623-634 (in particular the compounds described in the patent applications listed on page 634) and J Med Chem, 2000, 43, 527 which are all incorporated herein by reference. Particularly a PPAR alpha and/or gamma and/or delta

agonist refers to muraglitazar (BMS 298585), rivoglitazone (CS-011), netoglitazone (MCC-555), balaglitazone (DRF-2593, NN-2344), clofibrate, fenofibrate, bezafibrate, gemfibrozil, ciprofibrate, beclofibrate, etofibrate, gemcabene, pioglitazone, rosiglitazone, edaglitazone, LY-293111, MBX-2044, AVE-0847, AVE-8134, CLX-0921, DRF-10945, DRF-4832, LY-518674, naveglitazar (LY-818), LY-929, 641597, GW-590735, GW-677954, GW-501516, metaglidazen (MBX-102), T-131, SDX-101 E-3030, PLX-204, ONO-5129, KRP-101, R-483 (BM131258), TAK-559, K-111 (BM170744), netoglitazone (MCC-555; RWJ-241947; isaglitazone), FK-614 or TAK-654

10

Particularly a PPAR alpha and/or gamma and/or delta agonist refers to (S)-2-ethoxy-3-[4-(2-{4-methanesulphonyloxyphenyl}ethoxy) phenyl]propanoic acid (tesaglitazar) and pharmaceutically acceptable salts thereof.

Therefore in an additional feature of the invention, there is provided a combination of
15 a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof and a PPAR alpha and/or gamma agonist, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

Therefore in an additional feature of the invention, there is provided a method for producing a cholesterol lowering effect in a warm-blooded animal, such as man, in need of
20 such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof in simultaneous, sequential or separate administration with an effective amount of a PPAR alpha and/or gamma and/or delta agonist, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

25 According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a PPAR alpha and/or gamma and/or delta agonist, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in association with a pharmaceutically acceptable diluent or carrier.

30 According to a further aspect of the present invention there is provided a kit comprising a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a PPAR alpha and/or gamma and/or delta agonist, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

According to a further aspect of the present invention there is provided a kit comprising:

- a) a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in a first unit dosage form;
- 5 b) a PPAR alpha and/or gamma and/or delta agonist, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof; in a second unit dosage form; and
- c) container means for containing said first and second dosage forms.

According to a further aspect of the present invention there is provided a kit comprising:

- 10 a) a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, together with a pharmaceutically acceptable diluent or carrier, in a first unit dosage form;
- b) a PPAR alpha and/or gamma and/or delta agonist, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in a second unit dosage form; and
- 15 c) container means for containing said first and second dosage forms.

According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a PPAR alpha and/or gamma and/or delta agonist, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a
20 medicament for use in producing a cholesterol lowering effect in a warm-blooded animal, such as man.

According to a further aspect of the present invention there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof,
25 optionally together with a pharmaceutically acceptable diluent or carrier, with the simultaneous, sequential or separate administration of an effective amount of a PPAR alpha and/or gamma and/or delta agonist, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier to a warm-blooded animal, such as man in need of such therapeutic
30 treatment.

In another aspect of the invention, there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula (I), or a

pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the simultaneous, sequential or separate administration of an -agonists to the receptor HM74A (nicotinic acid receptor). HM74A receptor agonists may be nicotine acid derivatives. As used
5 herein "nicotinic acid derivative" means a compounds comprising a pyridine-3-carboxylate structure or a pyrazine-2-carboxylate structure. Examples of nicotinic acid derivatives include nicotinic acid, niceritrol, nicofuranose, NIASPAN® and acipimox.

HM74A receptor agonists may be anthranilic acid derivatives described in WO-2005016867
10 and WO-2005016870.

Other nicotinic receptor agonists are for example compounds described in WO2005011677, WO2004032928 and WO2004033431.

15 Therefore, in an additional feature of the invention, there is provided a combination of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof and a HM74A receptor agonists or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

Therefore in an additional feature of the invention, there is provided a method for
20 producing a cholesterol lowering effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof in simultaneous, sequential or separate administration with an effective amount of a HM74A receptor agonists, or a pharmaceutically acceptable salt, solvate, solvate
25 of such a salt or a prodrug thereof.

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a HM74A receptor agonists, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in
30 association with a pharmaceutically acceptable diluent or carrier.

In another aspect of the invention, there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula (I), or a

pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the simultaneous, sequential or separate administration of a mediator of reverse cholesterol transport i.e. a peptide (Apo A-1 mimetic peptides) or small molecule mediator of reverse
5 cholesterol transport e.g. those described in Circ. 2002;105:290, Circ. 2004.109:3215, Curr.Opinion in Lipidology 2004,15:645 or in WO2004094471.

In another aspect of the invention, the compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, may be administered in
10 association with an anti-obesity compound, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof, for example a pancreatic lipase inhibitor e.g. orlistat (EP 129,748) or an appetite (satiety) controlling substance for example sibutramine (GB 2,184,122 and US 4,929,629), a cannabinoid 1 (CB1) antagonist or inverse agonist, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof, for
15 example rimonabant (EP 656354) and as described in WO01/70700 or a melanin concentrating hormone (MCH) antagonist, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof, for example as described in WO 04/004726.

20 According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a nicotinic acid derivative, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the production of a cholesterol lowering effect in a warm-blooded animal, such as man.

25 In another aspect of the invention, the compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, may be administered in association with a bile acid sequestrant or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof. Suitable bile acid sequestrants include cholestyramine, cholestipol and cosevelam hydrochloride.

30 Therefore, in an additional feature of the invention, there is provided a combination of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof and a bile acid sequestrant or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

Therefore in an additional feature of the invention, there is provided a method for producing a cholesterol lowering effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt
5 or a prodrug thereof in simultaneous, sequential or separate administration with an effective amount of a bile acid sequestrant, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (I), or a pharmaceutically acceptable
10 salt, solvate, solvate of such a salt or a prodrug thereof, and a bile acid sequestrant, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in association with a pharmaceutically acceptable diluent or carrier.

According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a
15 prodrug thereof, and a bile acid sequestrant, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the production of a cholesterol lowering effect in a warm-blooded animal, such as man.

In another aspect of the invention, the compound of formula I, or a pharmaceutically
20 acceptable salt or solvate thereof, or a solvate of such a salt, may be administered in association with a cholesteryl ester transfer protein (CETP) inhibitor, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof, for example JTT-705, torcetrapib (CP-529414), Bay 194789 and those referenced and described in WO05033082 or WO 00/38725 page 7 line 22 - page 10, line 17 which are incorporated herein by reference.

25

In another aspect of the invention, the compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, may be administered in association with a acyl coenzymA: cholesterol O-acyltransferase (ACAT) inhibitor, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof, for
30 example pactimibe (CS-505), eflucimibe (F-12511) and SMP-797, avasimibe or K604.

In yet another aspect of the invention, the compound of formula I, association with modulators for example GW-4064 and INT-747 of nuclear receptors such as farnesoid or a

pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, may be administered in X receptor (FXR), or pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof

5 In another aspect of the invention, the compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, may be administered in association with a phytosterol compound, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof, for example stanols. An example of phytosterol analogs is FM-VP4.

10

In another aspect of the invention, the compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, may be administered in association with other therapies for the treatment of metabolic syndrome or type 2 diabetes and its associated complications, these include biguanide drugs, for example metformin,
15 phenformin and buformin, insulin (synthetic insulin analogues, amylin) and oral antihyperglycemics (these are divided into prandial glucose regulators and alpha-glucosidase inhibitors). An example of an alpha-glucosidase inhibitor is acarbose or voglibose or miglitol. An example of a prandial glucose regulator is repaglinide or nateglinide.

In another aspect of the invention, the compound of formula I, or a pharmaceutically
20 acceptable salt or solvate thereof, or a solvate of such a salt, may be administered in association with a sulfonylurea for example: glimepiride, glibenclamide (glyburide), gliclazide, glipizide, gliquidone, chlorpropamide, tolbutamide, acetohexamide, glycopyramide, carbutamide, glibonuride, glisoxepid, glybuthiazole, glibuzole, glyhexamide, glymidine, glypinamide, phenbutamide, tolcyclamide and tolazamide. Preferably the
25 sulfonylurea is glimepiride or glibenclamide (glyburide). More preferably the sulfonylurea is glimepiride. Therefore the present invention includes administration of a compound of the present invention in conjunction with one, two or more existing therapies described in this paragraph. The doses of the other existing therapies for the treatment of type 2 diabetes and its associated complications will be those known in the art and approved for use by regulatory
30 bodies for example the FDA and may be found in the Orange Book published by the FDA. Alternatively smaller doses may be used as a result of the benefits derived from the combination.

According to an additional further aspect of the present invention there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier,
5 with the simultaneous, sequential or separate administration one or more of the following agents selected from Group X:

- an antihypertensive compound (for example althiazide, benzthiazide, captopril, carvedilol, chlorothiazide sodium, clonidine hydrochloride, cyclothiazide, delapril hydrochloride, dilevalol hydrochloride, doxazosin mesylate, fosinopril sodium,
10 guanfacine hydrochloride, methyldopa, metoprolol succinate, moexipril hydrochloride, monatepil maleate, pelanserine hydrochloride, phenoxybenzamine hydrochloride, prazosin hydrochloride, primidolol, quinapril hydrochloride, quinaprilat, ramipril, terazosin hydrochloride, candesartan, candesartan cilexetil, telmisartan, amlodipine besylate, amlodipine maleate and bevantolol hydrochloride);
- 15 ➤ an angiotensin converting enzyme inhibitor (for example alacepril, alatriopril, altiopril calcium, ancovenin, benazepril, benazepril hydrochloride, benazeprilat, benzoylcaptopril, captopril, captopril-cysteine, captopril-glutathione, ceranapril, ceranopril, ceronapril, cilazapril, cilazaprilat, delapril, delapril-diacid, enalapril, enalaprilat, enapril, epicaptopril, foroxymithine, fosfenopril, fosenopril, fosenopril sodium, fosinopril, fosinopril sodium, fosinoprilat, fosinoprilic acid, glycopril,
20 hemorphin-4, idrapril, imidapril, indolapril, indolaprilat, libenzapril, lisinopril, lyciumin A, lyciumin B, mixanpril, moexipril, moexiprilat, moveltipril, muracein A, muracein B, muracein C, pentopril, perindopril, perindoprilat, pivalopril, pivopril, quinapril, quinapril hydrochloride, quinaprilat, ramipril, ramiprilat, spirapril, spirapril hydrochloride, spiraprilat, spiropril, spiropril hydrochloride, temocapril, temocapril
25 hydrochloride, teprotide, trandolapril, trandolaprilat, utibapril, zabicipril, zabiciprilat, zofenopril and zofenoprilat);
- an angiotensin II receptor antagonist (for example candesartan, candesartan cilexetil, losartan, valsartan, irbesartan, tasosartan, telmisartan and eprosartan);
- 30 ➤ an andrenergic blocker (for example bretylium tosylate, dihydroergotamine so mesylate, phentolamine mesylate, solypertine tartrate, zolertine hydrochloride, carvedilol or labetalol hydrochloride); an alpha andrenergic blocker (for example fenspiride hydrochloride, labetalol hydrochloride, proroxan and alfuzosin

- hydrochloride); a beta andrenergic blocker (for example acebutolol, acebutolol hydrochloride, alprenolol hydrochloride, atenolol, bunolol hydrochloride, carteolol hydrochloride, celiprolol hydrochloride, cetamolol hydrochloride, cicloprolol hydrochloride, dexpropranolol hydrochloride, diacetolol hydrochloride, dilevalol hydrochloride, esmolol hydrochloride, exaprolol hydrochloride, fleistolol sulfate, labetalol hydrochloride, levobetaxolol hydrochloride, levobunolol hydrochloride, metalol hydrochloride, metoprolol, metoprolol tartrate, nadolol, pamatolol sulfate, penbutolol sulfate, practolol, propranolol hydrochloride, sotalol hydrochloride, timolol, timolol maleate, tiprenolol hydrochloride, tolamolol, bisoprolol, bisoprolol fumarate and nebivolol); or a mixed alpha/beta andrenergic blocker;
- 5
- an andrenergic stimulant (for example combination product of chlorothiazide and methyldopa, the combination product of methyldopa hydrochlorothiazide and methyldopa, clonidine hydrochloride, clonidine, the combination product of chlorthalidone and clonidine hydrochloride and guanfacine hydrochloride);
- 10
- channel blocker, for example a calcium channel blocker (for example clentiazem maleate, amlodipine besylate, isradipine, nimodipine, felodipine, nilvadipine, nifedipine, teludipine hydrochloride, diltiazem hydrochloride, belfosdil, verapamil hydrochloride or fostedil);
- 15
- a diuretic (for example the combination product of hydrochlorothiazide and spironolactone and the combination product of hydrochlorothiazide and triamterene);
- 20
- anti-anginal agents (for example amlodipine besylate, amlodipine maleate, betaxolol hydrochloride, bevantolol hydrochloride, butoprozine hydrochloride, carvedilol, cinepazet maleate, metoprolol succinate, molsidomine, monatepil maleate, primidolol, ranolazine hydrochoride, tosifen or verapamil hydrochloride);
- 25
- vasodilators for example coronary vasodilators (for example fostedil, azaclozine hydrochloride, chromonar hydrochloride, clonitrate, diltiazem hydrochloride, dipyrindamole, droprenilamine, erythrityl tetranitrate, isosorbide dinitrate, isosorbide mononitrate, lidoflazine, mioflazine hydrochloride, mixidine, molsidomine, nicorandil, nifedipine, nisoldipine, nitroglycerine, oxprenolol hydrochloride,
- 30
- pentrinitrol, perhexiline maleate, prenylamine, propatyl nitrate, terodiline hydrochloride, tolamolol and verapamil);

- anti-coagulants (selected from argatroban, bivalirudin, dalteparin sodium, desirudin, dicumarol, Iyapolate sodium, nafamostat mesylate, phenprocoumon, tinzaparin sodium and warfarin sodium);
- antithrombotic agents (for example anagrelide hydrochloride, bivalirudin, cilostazol, dalteparin sodium, danaparoid sodium, dazoxiben hydrochloride, efegatran sulfate, enoxaparin sodium, fluretofen, ifetroban, ifetroban sodium, lamifiban, lotrafiban hydrochloride, napsagatran, orbofiban acetate, roxifiban acetate, sibrafiban, tinzaparin sodium, trifenagrel, abciximab and zolimomab aritox);
- fibrinogen receptor antagonists (for example roxifiban acetate, fradafiban, orbofiban, lotrafiban hydrochloride, tirofiban, xemilofiban, monoclonal antibody 7E3 and sibrafiban)
- platelet inhibitors (for example cilostezol, clopidogrel bisulfate, epoprostenol, epoprostenol sodium, ticlopidine hydrochloride, aspirin, ibuprofen, naproxen, sulindae, indomethacin, mefenamate, droxicam, diclofenac, sulfinpyrazone and piroxicam, dipyridamole);
- platelet aggregation inhibitors (for example acadesine, beraprost, beraprost sodium, ciprostone calcium, itezigrel, lifarizine, lotrafiban hydrochloride, orbofiban acetate, oxagrelate, fradafiban, orbofiban, tirofiban and xemilofiban)
- hemorrhheologic agents (for example pentoxifylline);
- lipoprotein associated coagulation inhibitors;
- Factor VIIa inhibitors;
- Factor Xa inhibitors;
- low molecular weight heparins (for example enoxaparin, nardoparin, dalteparin, certroparin, parnaparin, reviparin and tinzaparin);
- liver X receptor (LXR) agonists for example GW-3965 and those described in WO00224632, WO00103705, WO02090375 and WO00054759 (claim 1 and the named examples of these four application are incorporated herein by reference);
- microsomal triglyceride transfer protein inhibitors for example implitapide ,CP-346086, JTT-130, BMS-201038, R-103757 and those described in WO05/021486, WO03004020, WO03002533, WO02083658 and WO 00242291 (claim 1 and the named examples of these four application are incorporated herein by reference);
- ApoA1 expression inducer for example those described in WO2005032559

or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier to a warm-blooded animal, such as man in need of such therapeutic treatment.

Therefore, in an additional feature of the invention, there is provided a combination of
5 a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof and a compound from Group X or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

Therefore in an additional feature of the invention, there is provided a method for producing a cholesterol lowering effect in a warm-blooded animal, such as man, in need of
10 such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof in simultaneous, sequential or separate administration with an effective amount of a compound from Group X, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

15 According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a compound from Group X, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in association with a pharmaceutically acceptable diluent or carrier.

20 According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a compound from Group X, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the production of a cholesterol lowering effect in a warm-blooded animal, such as man.

25 In addition to their use in therapeutic medicine, the compounds of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, are also useful as pharmacological tools in the development and standardisation of *in vitro* and *in vivo* test systems for the evaluation of the effects of inhibitors of cholesterol absorption in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search
30 for new therapeutic agents.

What has been described above regarding the combination therapy with a compound of formula (I), and the use of a compound of formula (I) for the treatment or prophylaxis of various diseases and conditions also apply for compound (I2).

5 Many of the intermediates described herein are novel and are thus provided as a further feature of the invention. For example compounds of formula (XVI) show cholesterol absorption inhibitory activity when tested in the above referenced *in vitro* test assay and are thus claimed as a further feature of the invention.

Thus in a further feature of the invention, there is provided a compound of formula
10 (XVI), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

Therefore according to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (XVI), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof in
15 association with a pharmaceutically-acceptable diluent or carrier.

According to an additional aspect of the present invention there is provided a compound of the formula (XVI), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, for use in a method of prophylactic or therapeutic treatment of a warm-blooded animal, such as man.

20 Thus according to this aspect of the invention there is provided a compound of the formula (VI), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, for use as a medicament.

According to another feature of the invention there is provided the use of a compound of the formula (XVI), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a
25 prodrug thereof, in the manufacture of a medicament for use in the production of a cholesterol absorption inhibitory effect in a warm-blooded animal, such as man.

According to another feature of the invention there is provided the use of a compound of the formula (XVI) or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment of
30 hyperlipidaemic conditions in a warm-blooded animal, such as man.

According to a further feature of this aspect of the invention there is provided a method for producing a cholesterol absorption inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an

effective amount of a compound of formula (XVI), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

According to a further feature of this aspect of the invention there is provided a method of treating hyperlipidemic conditions in a warm-blooded animal, such as man, in need
5 of such treatment which comprises administering to said animal an effective amount of a compound of formula (XVI), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

In the above other pharmaceutical composition, process, method, use and medicament manufacture features, the alternative and preferred embodiments of the compounds of the
10 invention described herein also apply.

Examples

The invention will now be illustrated in the following non limiting Examples, in which standard techniques known to the skilled chemist and techniques analogous to those described
15 in these Examples may be used where appropriate, and in which, unless otherwise stated:

- (i) evaporations were carried out by rotary evaporation *in vacuo* and work up procedures were carried out after removal of residual solids such as drying agents by filtration;
- (ii) all reactions were carried out under an inert atmosphere at ambient temperature, typically in the range 18-25°C, with solvents of HPLC grade under anhydrous conditions, unless
20 otherwise stated;
- (iii) column chromatography (by the flash procedure) was performed on Silica gel 40-63 µm (Merck);
- (iv) yields are given for illustration only and are not necessarily the maximum attainable;
- (v) the structures of the end products of the formula (I) were generally confirmed by nuclear
25 (generally proton) magnetic resonance (NMR) and mass spectral techniques; magnetic resonance chemical shift values were measured in deuterated CDCl₃ (unless otherwise stated) on the delta scale (ppm downfield from tetramethylsilane); proton data is quoted unless otherwise stated; spectra were recorded on a Varian Mercury-300 MHz, Varian Unity plus-400 MHz, Varian Unity plus-600 MHz or on Varian Inova-500 MHz spectrometer unless
30 otherwise stated data was recorded at 400MHz; and peak multiplicities are shown as follows:
s, singlet; d, doublet; dd, double doublet; t, triplet; tt, triple triplet; q, quartet; tq, triple quartet; m, multiplet; br, broad; ABq, AB quartet; ABd, AB doublet, ABdd, AB doublet of doublets; dABq, doublet of AB quartets;

Mass spectra were recorded on one of the following instruments: LCT, QTOF, ZQ Mass
5 spectrometer, all from Waters.

LC-MS:

Separation was performed using Agilent 1100 Series Modules or Waters 1525 pump on a
Synergi MAX-RP (Phenomenex) C12 3x50 mm 4 μ m with gradient elution.

Samples were injected using Waters 2700 Sample Manager.

10 Mobile phases:

Generic gradients were applied from 5% to 95% acetonitrile.

Buffers containing 10 mM ammonium acetate or 5 mM ammonium formate/5mM formic
acid were used.

The mass spectra were recorded with a Waters ZQ2000 or Waters ZMD equipped with an
15 electrospray interface, switching positive and negative ionization mode. UV spectra were
collected by a Agilent 1100 PDA or Waters 2996 DAD and the evaporative light scattering
(ELS) signal by a Sedere Sedex 55 or 75.

Data collection and evaluation were performed using the MassLynx software.

Accurate mass data were determined using either a LCT or QTOF MS (Waters) with leucine
20 enkephaline (m/z 556.2771) as lockmass. Unless otherwise stated the mass ion quoted is
(MH⁺).

Unless further details are specified in the text, analytical high performance liquid
chromatography (HPLC) was performed on Prep LC 2000 (Waters), Cromasil C₈, 7 μ m,
25 (Akzo Nobel); MeCN and de-ionised water 10 mM ammonium acetate as mobile phases, with
suitable composition;

(vii) intermediates were not generally fully characterised and purity was assessed by thin layer
chromatography (TLC), HPLC, infra-red (IR), MS or NMR analysis;

(viii) where solutions were dried sodium sulphate was the drying agent; and

30 (ix) the following abbreviations may be used hereinbefore or hereinafter:-

DCM dichloromethane;

DMF *N,N*-dimethylformamide;

TBTU *o*-Benzotriazol-1-yl-*N,N,N',N'*-tetramethyluronium tetrafluoroborate;

EtOAc	ethyl acetate;
MeCN	acetonitrile;
TFA	trifluoroacetic acid;
DMAP	4-(dimethylamino)pyridine;
5 BSA	<i>N,O</i> -Bis(trimethylsilyl)acetamide; and
TBAF	tetrabutylammonium fluoride;
NMM	<i>N</i> -methyl morpholine;
TEA	triethylamine;
DBN	1,5-diazabicyclo-[4,3,0]-non-5-ene.

10

Examples

It will be appreciated by those skilled in the art that the examples may be modified within the
 15 realms of the invention, why the invention is not limited to particular embodiments.

Example 1

N-({4-[(2*R*,3*R*)-3-{[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-methyl-D-valine

20

To a solution of *N*-[(4-{(2*R*,3*R*)-1-(4-fluorophenyl)-3-[(3-nitropyridin-2-yl)dithio]-4-oxoazetidin-2-yl]phenoxy)acetyl]glycyl-3-methyl-D-valine (0.030 g, 0.045 mmol) in acetone/water (2 / 0.5 ml) was added triphenylphosphine (0.012 g, 0.045 mmol). After 30 minutes the solvent was evaporated and to the residue was added dichloromethane (2 ml) and
 25 triethylamine (0.018 g, 0.179 mmol) followed by the addition of 2-bromo-1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethanone (0.029 g, 0.112 mmol). After 10 minutes the reaction was quenched by the addition of water (1 ml) followed by concentration of the mixture. MeOH (2 ml) was added followed by the addition of sodium borohydride (0.017 g, 0.447 mmol). Full conversion to the corresponding alcohol was achieved within 5 minutes. The reaction was
 30 quenched by the addition of 0.1M NH₄OAc buffer (1 ml). Preparative HPLC of the mixture using an eluent of 20-45% CH₃CN in 0.1M NH₄OAc buffer followed by freeze drying of pure fractions afforded the desired compound. *m/z*: 694.7 (*M* - 1). ¹H NMR [(CD₃)₂SO], 400

MHz] δ 0.89 (s, 9H), 2.78-2.89 (m, 2H), 3.82 (d, 2H), 4.05-4.28 (m, 6H), 4.51 (s, 2H), 4.55-4.61 (m, 1H), 5.01-5.03 (m, 1H), 6.72-7.37 (m, 11H), 7.81-7.87 (m, 1H), 8.25 (t, 1H).

5 Example 2

***N*-({4-[(2*R*,3*R*)-3-{[2-(1,3-Benzodioxol-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-cyclohexyl-D-alanine**

To a solution of {4-[(2*R*,3*R*)-3-{[2-(1,3-benzodioxol-5-yl)-2-oxoethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetic acid (Method 7) (0.025 g, 0.049 mmol) and NMM (0.020 ml, 0.178 mmol) in DMF (3 ml) at RT was added TBTU (0.020 g, 0.062 mmol). The reaction mixture was stirred for 90 min after which glycyl-3-cyclohexyl-D-alanine (Method 9) (0.012 g, 0.035 mmol) was added. The mixture was stirred for 20 h before the reaction was quenched by the addition of water (1 ml). The mixture was diluted with methanol (2 ml) and then NaBH₄ (0.028 g, 0.740 mmol) was added. After 15 min the reaction was quenched by the addition of an aqueous solution of hydrochloric acid (1M, 1 ml) and most of the methanol was removed under reduced pressure. The remaining solution was purified by preparative HPLC using a gradient of 20-60% MeCN in a 0.1M ammonium acetate buffer as eluent. Freeze-drying of the pure fractions gave the desired product as.

M/z (ES⁻): 721.1. ¹H NMR (DMSO, 400 MHz): δ 0.69-1.69 (m, 13H), 2.77-2.91 (m, 2H), 3.71-3.78 (m, 2H), 4.10-4.19 (m, 1H), 4.21-4.27 (m, 1H), 4.49 (s, 2H), 4.55-4.65 (m, 1H), 4.99-5.04 (m, 1H), 5.88-5.96 (m, 2H), 6.69-6.85 (m, 3H), 6.92-6.99 (m, 2H), 7.07-7.24 (m, 4H), 7.31-7.38 (m, 2H), 7.93-8.02 (m, 1H), 8.17-8.25 (m, 1H).

25

Example 3

***N*-({4-[(2*R*,3*R*)-3-{[2-(1,3-Benzodioxol-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-methyl-D-valine**

To a solution of {4-[(2*R*,3*R*)-3-{[2-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetic acid (0.006 g, 0.012 mmol) and NMM (0.007 ml, 0.064 mmol) in DMF (3 ml) at RT was added TBTU (0.005 g, 0.016 mmol). The reaction mixture was stirred for 60 min after which glycyl-3-methyl-D-valine (Method 10)

(0.003 g, 0.016 mmol) was added. The mixture was stirred for 4 h before the solution was purified by preparative HPLC using a gradient of 20-60% MeCN in a 0.1M ammonium acetate buffer as eluent. Freeze-drying of the pure fractions gave the desired product.

5 M/z (ES⁻): 681.1. ¹H NMR (DMSO, 400 MHz): δ 0.86 (s, 9H), 2.75-2.94 (m, 2H), 3.74-3.82 (m, 2H), 3.92-4.01 (m, 1H), 4.21-4.32 (m, 1H), 4.49 (s, 2H), 4.56-4.65 (m, 1H), 4.98-5.04 (m, 1H), 5.90-5.95 (m, 2H), 6.70-6.84 (m, 3H), 6.92-6.99 (m, 2H), 7.08-7.24 (m, 4H), 7.31-7.38 (m, 2H), 7.63-7.78 (m, 1H), 8.23-8.29 (m, 1H).

10 Example 4

N-({4-[(2*R*,3*R*)-3-{[2-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-β,β-dimethyl-D-phenylalanine

To a stirred solution of *N*-({4-[(2*R*,3*R*)-3-{[2-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycine (15.6 mg, 0.027 mmol) in DMF
15 (2 ml) was added *N*-methylmorpholine (15 μl, 0.091 mmol). TBTU (12.2 mg, 0.038 mmol) was added and the reaction mixture was stirred at 30°C for 1 hour. β,β-dimethyl-D-phenylalanine trifluoroacetate (10.2 mg, 0.033 mmol) was added and the mixture was stirred at ambient temperature overnight. The solution was purified with preparative HPLC on a C8
20 column, UV 240/260 nm. A gradient from 20 to 45 % MeCN in 0.1M NH₄OAc buffer was used as eluent. The pure fractions were collected and the MeCN was removed under reduced pressure. The remaining water solution was acidified to pH 1 with HCl (1M) and extracted with DCM. The organic phase was passed through a phase separator and concentrated under reduced pressure. The residue was dissolved in MeCN and water. After lyophilisation, the
25 title compound was obtained. H-NMR (400 MHz, DMSO-*d*₆): 1.28 (d, 6H), 2.74-2.92 (m, 2H), 3.58-3.82 (m, 2H) 4.30-4.21 (m, 1H), 4.46 (s, 2H), 4.53-4.65 (m, 2H) 5.00 (b, 0.5H), 5.03 (b, 0.5H), 5.53 (b, 1H), 5.90-5.94 (m, 2H), 6.70-6.79 (m, 2H), 6.82 (s, 1H), 6.90-6.98 (m, 2H), 7.07-7.15 (m, 3H), 7.18-7.26 (m, 4H), 7.27-7.37 (m, 4H), 7.78 (b, 1H), 8.19 (t, 1H). M/z: 742.68 (M-1).

30

Example 5

***N*-({4-[(2*R*,3*R*)-3-{[2-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-D-valine**

To a stirred solution of *N*-({4-[(2*R*,3*R*)-3-{[2-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycine (12.8 mg, 0.023 mmol) in DMF (2 ml) was added *N*-methylmorpholine (15 μ l, 0.091 mmol). TBTU (8.8 mg, 0.027 mmol) was added and the reaction mixture was stirred at 30°C for 1 hour. D-valine (4.5 mg, 0.038 mmol) was added and the mixture was stirred at ambient temperature overnight. The solution was purified with preparative HPLC on a C8 column, UV 240/260 nm. A gradient from 20 to 45 % MeCN in 0.1M NH₄OAc buffer was used as eluent. The pure fractions were collected and the MeCN was removed under reduced pressure. The remaining water solution was acidified to pH 1 with HCl (1M) and extracted with DCM. The organic phase was passed through a phase separator and concentrated under reduced pressure. The residue was dissolved in MeCN and water. After lyophilisation, the title compound was obtained. H-NMR (400 MHz, DMSO-*d*₆): 0.80 (bs, 6H), 1.92-2.04 (m, 1H), 2.77-2.90 (m, 2H), 3.77 (bs, 2H), 3.94-4.10 (b, 1H), 4.22-4.30 (m, 1H), 4.49 (s, 2H), 4.56-4.64 (m, 1H), 4.99-5.03 (m, 1H), 5.90-5.94 (m, 2H), 6.70-6.79 (m, 2H), 6.82 (s, 1H), 6.96 (d, 2H), 7.09-7.15 (m, 2H), 7.18-7.24 (m, 2H), 7.34 (d, 2H), 8.23 (bs, 1H). M/z: 666.67 (M-1).

Example 6

***N*-({4-[(2*R*,3*R*)-3-{[2-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]thio}-1-(4-chlorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-cyclohexyl-D-alanine**

To a stirred solution of {4-[(2*R*,3*R*)-3-{[2-(1,3-benzodioxol-5-yl)-2-oxoethyl]thio}-1-(4-chlorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetic acid (35.4 mg, 0.067 mmol) in DMF (3 ml) was added *N*-methylmorpholine (35 μ l, 0.23 mmol). TBTU (29.3 mg, 0.091 mmol) was added and the reaction mixture was stirred at 30°C for 1 hour. Glycyl-3-cyclohexyl-D-alanine (18.4 mg, 0.081 mmol) was added and the mixture was stirred at ambient temperature for 60 hours. The formation of the ketone of the title compound was confirmed. M/z: 736.67 (M+1) and 734.71 (M-1). Without further purification, methanol (2 ml) and sodium borohydride (28.0 mg, 0.740 mmol) was added and the mixture was stirred for 20 minutes. Ammonium acetate (38.4 mg) was added and the solution was purified with preparative HPLC on a C8 column, UV 240/260 nm. A gradient from 20 to 45 % MeCN in 0.1M NH₄OAc buffer was

used as eluent. The pure fractions were collected and the MeCN was removed under reduced pressure. The remaining water solution was acidified to pH 1 with HCl (1M) and extracted with DCM. The organic phase was passed through a phase separator and concentrated under reduced pressure. The residue was dissolved in MeCN and water. After lyophilisation, the title compound was obtained. ¹H-NMR (400 MHz, DMSO-d₆): 0.70-1.68 (m, 13H), 2.78-2.88 (m, 2H), 3.75 (d, 2H), 4.13-4.21 (m, 1H), 4.23-4.28 (m, 1H), 4.49 (s, 2H), 4.56-4.64 (m, 1H), 5.02 (d, 0.5H), 5.04 (d, 0.5H), 5.56 (b, 1H), 6.70-6.79 (m, 2H), 6.82 (s, 1H), 6.96 (d, 2H), 7.18 (d, 2H), 7.30-7.37 (m, 4H), 8.04 (b, 1H), 8.20 (t, 1H). M/z: 736.69 (M-1).

10 Example 7

N-({4-[(2*R*,3*R*)-3-{[2-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-D-lysine

To a stirred solution of *N*-({4-[(2*R*,3*R*)-3-{[2-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycine (11.3 mg, 0.020 mmol) in DCM (2 ml) were added *tert*-butyl *N*⁶-(*tert*-butoxycarbonyl)-D-lysinate hydrochloride (9.5 mg, 0.028 mmol), *N*-methylmorpholine (15 μl, 0.091 mmol) and TBTU (11.0 mg, 0.034 mmol). The reaction mixture was stirred at ambient temperature for 3 hours. The formation of the intermediate *tert*-butyl *N*-({4-[(2*R*,3*R*)-3-{[2-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-*N*⁶-(*tert*-butoxycarbonyl)-D-lysinate was confirmed. M/z: 852.23 (M-1). The solvent was removed under reduced pressure and the residue was dissolved in formic acid (2 ml). The mixture was stirred at ambient temperature for 48 hours. The solvent was co-evaporated with toluene and the residue was purified with preparative HPLC on a C8 column, UV 240/260 nm. A gradient from 20 to 45 % MeCN in 0.1M NH₄OAc buffer was used as eluent. The MeCN was removed under reduced pressure and the residue was lyophilised to give the title. ¹H-NMR (400 MHz, DMSO-d₆): 1.08-1.32 (m, 2H), 1.37-65 (m, 4H), 2.63 (t, 2H), 2.77-2.92 (m, 2H), 3.70 (d, 2H), 3.76-3.82 (m, 1H), 4.25 (d, 0.5H), 4.28 (d, 0.5H), 4.50 (s, 2H), 4.57-4.64 (m, 1H), 5.00 (d, 0.5H), 5.02 (d, 0.5H), 5.90-5.94 (m, 2H), 6.70-6.81 (m, 2H), 6.83 (s, 1H), 6.96 (d, 2H), 7.08-7.16 (m, 2H), 7.17-7.24 (m, 2H), 7.34 (d, 2H), 7.45-7.55 (m, 1H), 8.37-8.43 (m, 1H). M/z: 697.32 (M+1) and 695.39 (M-1).

Example 8

N-({4-[(2*R*,3*R*)-3-{[2-(1,3-Benzodioxol-5-yl)-2-hydroxyethyl]thio}-1-(4-methylphenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-cyclohexyl-D-alanine

- 5 To a solution of {4-[(2*R*,3*R*)-3-{[2-(1,3-benzodioxol-5-yl)-2-oxoethyl]thio}-1-(4-methylphenyl)-4-oxoazetidin-2-yl]phenoxy}acetic acid (0.020 g, 0.040 mmol) and NMM (0.013 ml, 0.116 mmol) in DMF (3 ml) at RT was added TBTU (0.020 g, 0.062 mmol). The reaction mixture was stirred for 30 min after which glycyl-3-cyclohexyl-D-alanine (0.011 g, 0.032 mmol) was added. The mixture was stirred for 22 h before the reaction was quenched
10 by the addition of water (1 ml). The mixture was diluted with MeOH (2 ml) and added NaBH₄ (0.028 g, 0.740 mmol). After 15 min the reaction was quenched by the addition of an aqueous solution of hydrochloric acid (1M, 1 ml) and most of the methanol was removed under reduced pressure. The remaining solution was purified by preparative HPLC using a gradient of 20-60% MeCN in a 0.1M ammonium acetate buffer as eluent. Freeze-drying of
15 the pure fractions gave the desired product.

M/z (ES⁻): 716.7. ¹H NMR (DMSO, 400 MHz): δ 0.70-1.70 (m, 13H), 2.16 (s, 3H), 2.77-2.90 (m, 2H), 3.70-3.78 (m, 2H), 4.10-4.22 (m, 2H), 4.48 (s, 2H), 4.55-4.64 (m, 1H), 4.93-5.00 (m, 1H), 5.88-5.97 (m, 2H), 6.69-6.85 (m, 3H), 6.91-7.00 (m, 2H), 7.02-7.11 (m, 4H), 7.29-7.36 (m, 2H), 7.93-8.04 (m, 1H), 8.17-8.25 (m, 1H).

20

Example 9

N-({4-[(2*R*,3*R*)-3-{[2-(1,3-Benzodioxol-5-yl)-2-hydroxyethyl]thio}-1-(4-methylphenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-methyl-D-valine

25

- To a solution of {4-[(2*R*,3*R*)-3-{[2-(1,3-benzodioxol-5-yl)-2-oxoethyl]thio}-1-(4-methylphenyl)-4-oxoazetidin-2-yl]phenoxy}acetic acid (0.020 g, 0.040 mmol) and NMM (0.013 ml, 0.116 mmol) in DMF (3 ml) at RT was added TBTU (0.016 g, 0.050 mmol). The reaction mixture was stirred for 30 min after which glycyl-3-methyl-D-valine (0.009 g, 0.048
30 mmol) was added. The mixture was stirred for 15 h before the reaction was quenched by the addition of water (1 ml). The mixture was diluted with MeOH (2 ml) and added NaBH₄ (0.017 g, 0.449 mmol). After 15 min the reaction was quenched by the addition of an aqueous solution of hydrochloric acid (1M, 1 ml) and most of the methanol was removed under

reduced pressure. The remaining solution was purified by preparative HPLC using a gradient of 20-60% MeCN in a 0.1M ammonium acetate buffer as eluent. Freeze-drying of the pure fractions gave the desired product.

M/z (ES⁻): 676.6. ¹H NMR (DMSO, 400 MHz): δ 0.87 (s, 9H), 2.16 (s, 3H), 2.76-2.90 (m, 2H), 3.77-3.84 (m, 2H), 4.01-4.08 (m, 1H), 4.16-4.22 (m, 1H), 4.48 (s, 2H), 4.56-4.64 (m, 1H), 4.94-4.99 (m, 1H), 5.89-5.95 (m, 2H), 6.69-6.84 (m, 3H), 6.91-6.98 (m, 2H), 7.02-7.10 (m, 4H), 7.28-7.35 (m, 2H), 7.78-7.88 (m, 1H), 8.19-8.26 (m, 1H).

10 Example 10

***N*-({4-[(2*R*,3*R*)-3-{{(2*S* or *R*)-2-(1,3-benzodioxol-5-yl)-2-hydroxyethyl}thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl}phenoxy)acetyl)glycyl-3-methyl-D-valine**

The diastereomeric mixture of *N*-({4-[(2*R*,3*R*)-3-{{2-(1,3-benzodioxol-5-yl)-2-hydroxyethyl}thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl}phenoxy)acetyl)glycyl-3-methyl-D-valine (Example 3); (10.8 mg, 0.016 mmol) was separated on two successive Chiralpak AD columns (250 x 20 mm, 10 μm) at 40°C using ethanol / heptane / formic acid / triethylamine (90/10/0.1/0.05) in 1.0 ml/min as mobile phase. UV-detection at 254 nm. The fraction of the first eluting diastereomer was concentrated and extracted between DCM and water. The organic phase was washed with water, dried with Na₂SO₄ and concentrated to yield the title compound. ¹H-NMR (DMSO, 400 MHz): δ 0.90 (s, 9H), 2.80-2.95 (m, 2H), 3.84 (d, 2H), 4.08 (d, 1H), 4.29 (d, 1H), 4.53 (s, 2H), 4.63-4.68 (m, 1H), 5.05 (d, 1H), 5.96 (s, 2H), 6.74-6.82 (m, 2H), 6.86 (s, 1H), 7.00 (d, 2H), 7.12-7.20 (m, 2H), 7.21-7.28 (2H), 7.38 (d, 2H), 7.84 (d, 1H), 8.28 (t, 1H).

25

Example 11

***N*-({4-[(2*R*,3*R*)-3-{{(2*R* or *S*)-2-(1,3-benzodioxol-5-yl)-2-hydroxyethyl}thio}-1-(4-fluorophenyl)-4-oxo azetidin-2-yl}phenoxy)acetyl)glycyl-3-methyl-D-valine**

30

The diastereomeric mixture of *N*-({4-[(2*R*,3*R*)-3-{{2-(1,3-benzodioxol-5-yl)-2-hydroxyethyl}thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl}phenoxy)acetyl)glycyl-3-methyl-D-valine (10.8 mg, 0.016 mmol) was separated as described in Example 10. The title

compound was obtained as the second eluting diastereomer. ¹H-NMR (DMSO, 400 MHz): δ 0.90 (s, 9H), 2.84-2.95(m, 2H), 3.84 (d, 2H), 4.07 (d, 1H), 4.27 (d, 1H), 4.53 (s, 2H), 4.60-4.65 (m, 1H), 5.07 (d, 1H), 5.96 (d, 2H), 6.74-6.84 (m, 2H), 6.86 (s, 1H), 7.00 (d, 2H), 7.12-7.20 (m, 2H), 7.21-7.28 (m, 2H), 7.38 (d, 2H), 7.83 (d, 1H), 8.28 (t, 1H).

5

Example 12

N-({4-[(2*R*,3*R*)-3-{{(2*S* or *R*)-2-(1,3-benzodioxol-5-yl)-2-hydroxyethyl}thio}-1-(4-
10 fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-cyclohexyl-D-alanine

The title compound was obtained as the first eluting diastereomer in the chromatographic separation of *N*-({4-[(2*R*,3*R*)-3-{{2-(1,3-benzodioxol-5-yl)-2-hydroxyethyl}thio}-1-(4-
15 fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-cyclohexyl-D-alanine (Example 2) (12 mg, 0.017 mmol). The chromatographic conditions used were as those described in Example 10. The title compound was obtained. ¹H-NMR (DMSO, 400 MHz): δ 0.75-0.96 (m, 2H), 1.06-1.20 (m, 3H), 1.24-1.37 (m, 2H), 1.41-1.72 (m, 6H), 2.81-2.93 (m, 2H), 3.80 (d, 2H), 4.02 (t, 1H), 4.28 (d, 1H), 4.53 (s, 2H), 4.61-4.69 (m, 1H), 5.05 (d, 1H), 5.56 (d, 1H),
20 5.96 (s, 2H), 6.72-6.82 (m, 2H), 6.85 (s, 1H), 7.00 (d, 2H), 7.11-7.20 (m, 2H), 7.21-7.28 (m, 2H), 7.38 (d, 2H), 8.13 (d, 1H), 8.22 (t, 1H).

Example 13

25 *N*-({4-[(2*R*,3*R*)-3-{{(2*R* or *S*)-2-(1,3-benzodioxol-5-yl)-2-hydroxyethyl}thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-cyclohexyl-D-alanine

The diastereomeric mixture of *N*-({4-[(2*R*,3*R*)-3-{{2-(1,3-benzodioxol-5-yl)-2-hydroxyethyl}thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-
30 cyclohexyl-D-alanine 12 mg, 0.017 mmol) was separated as described in Example 12. The title compound was obtained as the second eluting. ¹H-NMR (DMSO, 400 MHz): δ 0.76-0.96 (m, 2H), 1.05-1.21 (m, 3H), 1.24-1.37 (m, 2H), 1.41-1.72 (m, 6H), 2.84-2.94 (m, 2H), 3.79 (d, 2H), 4.18-4.26 (m, 1H), 4.27 (d, 1H), 4.52 (s, 2H), 4.59-4.66 (m, 1H), 5.07 (d, 1H), 5.56 (brs,

1H), 5.96 (d, 2H), 6.742-6.84 (m, 2H), 6.86 (s, 1H), 7.00 (d, 2H), 7.12-7.20 (m, 2H), 7.21-7.28 (m, 2H), 7.38 (d, 2H), 8.05-8.13 (m, 1H), 8.23 (t, 1H).

Example 14

5 N-({4-[(2R,3R)-3-{[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-cyclohexyl-D-alanine

To a solution of {4-[(2R,3R)-3-{[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxoethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetic acid (0.020 g, 0.038 mmol) (Method 29) in
10 DMF (1 ml) was added N-methylmorpholine (0.010 g, 0.099 mmol) followed by the addition of 3,4-dichlorophenol (0.008 g, 0.051 mmol) and TBTU (0.012 g, 0.038 mmol). After 2h, the intermediate 3,4-dichlorophenylester (3,4-dichlorophenyl {4-[(2R,3R)-3-{[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxoethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetate) had been formed. Glycyl-3-cyclohexyl-D-alanine (0.010 g, 0.046 mmol) and lithium chloride
15 (0.024 g, 0.57 mmol) were added and the mixture was allowed to stir at room temperature for 1h. Methanol (1 ml) was added followed by the addition of NaBH₄ (0.022 g, 0.573 mmol). Full conversion to the corresponding alcohol had been obtained within 5 minutes. The mixture was purified through preparative HPLC using an eluent of 10-50% CH₃CN in 0.1M NH₄OAc buffer. Freeze drying of pure fractions afforded the desired. ¹H NMR [(CD₃)₂SO],
20 400 MHz] δ 0.73-1.67 (m, 13H), 2.76-2.87 (m, 2H), 3.73 (d, 2H), 4.07-4.14 (m, 1H), 4.14-4.18 (m, 4H), 4.24-4.26 (m, 1H), 4.48 (s, 2H), 4.52-4.60 (m, 1H), 4.98-5.03 (m, 1H), 6.70-7.35 (m, 11H), 7.85-7.90 (m, 1H), 8.20-8.24 (m, 1H).

25 Example 15

N-((2R)-2-[(4-[(2R,3R)-3-{[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)amino]-2-phenylacetyl)-L-serine

{4-[(2R,3R)-3-{[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxoethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetic acid (22 mg, 0.042 mmol), N-methylmorpholine (12 µl, 0.11 mmol), TBTU (15 mg, 0.046 mmol) and *tert*-butyl N-[(2R)-2-amino-2-phenylacetyl]-O-(*tert*-butyl)-L-serinate (22 mg, 0.063 mmol) were added to methylene chloride (2 ml) and the reaction mixture was stirred for 2 h. at room temperature. The solvent was evaporated under reduced pressure and formic acid (2 ml) was added. The mixture was stirred for 16 h. at room

temperature and at 50 °C for 4 h. The solvent was evaporated at reduced pressure and then co-evaporated with toluene twice. To the residue was added methanol (1 ml) and NaBH₄ (26 mg, 0.34 mmol) was added during 15 min. The reaction mixture was stirred for 2h. at room temperature and was then purified by preparative HPLC using acetonitril/ammonium acetate buffer (40:60) as eluent. The collected fractions were lyophilized to obtain the title compound.

(¹H-NMR, 500 MHz, DMSO-d₆): 2.8-2.9 (m, 2H), 3.2-3.3 (m, 1H), 3.45-3.5 (m, 1H), 4.2 (s, 4H), 4.3 (s, 1H), 4.55- 4.7, 5.05 (d, 1H), 5.55 (bs, 1H), 5.65 (d, 1H), 6.7-7.4 (m, 16H), 8.15 (bs, 1H), 8.6 (d, 1H)

10

Example 16

15 **(R)-3-Cyclohexyl-2-[2-(2-{4-[(2R,3R)-3-[(R or S)-2-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-2-hydroxy-ethylsulfanyl]-1-(4-fluoro-phenyl)-4-oxo-azetidin-2-yl]-phenoxy}-acetyl-amino)-acetyl-amino]-propionic acid**

20 To a solution {4-[(2R,3R)-3-[(R or S)-2-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-2-hydroxy-ethylsulfanyl]-1-(4-fluoro-phenyl)-4-oxo-azetidin-2-yl]-phenoxy}-acetic acid (60 mg, 0.114 mmol) in DMF (2 mL) was added 4-chlorophenol (15 mg, 0.117 mmol), N-methylmorpholine (75 µL, 0.682 mmol) and TBTU (37 mg, 0.115 mmol). The mixture was stirred for 1 h at room temperature before (R)-2-(2-amino-acetyl-amino)-3-cyclohexyl-propionic acid (39 mg, 0.171 mmol) and lithium chloride (100 mg, 2.36 mmol) were added. The reaction mixture was stirred at room temperature for 13 h and then at 30°C for 3h. The reaction was quenched by the addition of water (2 mL) and the resulting mixture was purified by preparative HPLC using a gradient of 20-50% MeCN in a 0.1M ammonium acetate buffer as eluent. Freeze-drying of the pure fractions gave the desired product.

30

¹H-NMR (DMSO, 400 MHz): δ 0.70-0.95 (m, 2H), 1.00-1.73 (m, 11H), 2.80-2.92 (m, 2H), 3.77 (d, 2H), 4.12-4.24 (m, 5H), 4.27 (d, 1H), 4.51 (s, 2H), 4.54-4.61 (m, 1H), 5.04 (d, 1H),

5.53 (bs, 1H), 6.72-6.81 (m, 3H), 6.95-7.03 (m, 2H), 7.10-7.28 (m, 4H), 7.34-7.42 (m, 2H), 7.99 (d, 1H), 8.21-8.28 (m, 1H).

5 Example 17

(R)-2-[2-(2-{4-[(2R,3R)-3-[(R or S)-2-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-2-hydroxy-ethylsulfanyl]-1-(4-fluoro-phenyl)-4-oxo-azetidin-2-yl]-phenoxy}-acetylamino)-acetylamino]-3,3-dimethyl-butyric acid

10

To a solution of {4-[(2R,3R)-3-[(R or S)-2-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-2-hydroxy-ethylsulfanyl]-1-(4-fluoro-phenyl)-4-oxo-azetidin-2-yl]-phenoxy}-acetic acid (19 mg, 0.036 mmol) in DMF (1.5 mL) was added N-methylmorpholine (10 μ L, 0.089 mmol) and TBTU (13 mg, 0.040 mmol). The mixture was stirred for 30 min at room temperature before (R)-2-
15 (2-amino-acetylamino)-3,3-dimethyl-butyric acid (7 mg, 0.037 mmol) was added. After 16 h, the reaction was quenched by the addition of water (0.5 mL). The solution was purified by preparative HPLC using a gradient of 20-40% MeCN in a 0.1M ammonium acetate buffer as eluent. Freeze-drying of the pure fractions gave the desired product.

20 ¹H-NMR (DMSO, 500 MHz): δ 0.88 (s, 9H), 2.80-2.92 (m, 2H), 3.80 (d, 2H), 3.99 (d, 1H), 4.19 (s, 4H), 4.28 (d, 1H), 4.52 (s, 2H), 4.54-4.61 (m, 1H), 5.04 (d, 1H), 6.71-6.81 (m, 3H), 6.95-7.02 (m, 2H), 7.11-7.19 (m, 2H), 7.20-7.27 (m, 2H), 7.34-7.40 (m, 2H), 7.69-7.78 (m, 1H), 8.26-8.32 (m, 1H).

25


Example 18

(R)-2-[2-(2-{4-[(2R,3R)-3-[(R or S)-2-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-2-hydroxy-ethylsulfanyl]-1-(4-fluoro-phenyl)-4-oxo-azetidin-2-yl]-phenoxy}-acetylamino)-
30 acetylamino]-3-methyl-butyric acid

To a solution of {4-[(2R,3R)-3-[(R or S)-2-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-2-hydroxy-ethylsulfanyl]-1-(4-fluoro-phenyl)-4-oxo-azetidin-2-yl]-phenoxy}-acetic acid (19 mg, 0.036 mmol) in DMF (1.5 mL) was added N-methylmorpholine (15 μ L, 0.138 mmol) and TBTU (13 mg, 0.040 mmol). The mixture was stirred for 30 min at RT before (R)-2-(2-amino-5 acetylamino)-3-methyl-butyric acid (8 mg, 0.038 mmol) was added. After 16 h, the reaction was quenched by the addition of water (1 mL). This solution was purified by preparative HPLC using a gradient of 20-40% MeCN in a 0.1M ammonium acetate buffer as eluent. Freeze-drying of the pure fractions gave the desired product.

¹H-NMR (DMSO, 500 MHz): δ 0.76-0.84 (m, 6H), 1.95-2.06 (m, 1H), 2.81-2.92 (m, 2H), 3.79 (d, 2H), 3.93-4.01 (m, 1H), 4.19 (s, 4H), 4.28 (d, 1H), 4.52 (s, 2H), 4.55-4.61 (m, 1H), 5.04 (d, 1H), 6.71-6.81 (m, 3H), 6.96-7.02 (m, 2H), 7.11-7.18 (m, 2H), 7.20-7.27 (m, 2H), 7.34-7.40 (m, 2H), 7.65-7.74 (m, 1H), 8.26-8.33 (m, 1H).

The following compounds could be prepared by the procedure of Example 14, but wherein different protecting groups may be used.



X	R1	R2	R3	R4	R5
CH ₂ CH ₂	H	CH ₂ C ₆ H ₅	H	H	F
CH ₂ CH ₂	H	CH ₂ C ₆ H ₅ -p-OH	H	H	F
CH ₂ CH ₂	H	CH ₂ C ₆ H ₅ -p-CN	H	H	F
CH ₂ CH ₂	H	CH ₂ CH ₂ CH ₂ NH ₂	H	H	F
CH ₂ CH ₂	H	CH ₂ CH ₂ CH ₂ CH ₂ NH ₂	H	H	F
CH ₂ CH ₂	H	C(CH ₃) ₂ C ₆ H ₅	H	H	F
CH ₂ CH ₂	H	CH ₂ CH(CH ₃) ₂	H	H	F
CH ₂ CH ₂	H	CH(CH ₃) ₂	CH ₃	H	F
CH ₂ CH ₂	H	R ₂ , R ₄ = CH ₂ CH ₂ CH ₂	H	R ₂ , R ₄ = CH ₂ CH ₂ CH ₂	F
CH ₂ CH ₂	H	CH ₂ CH ₂ CH ₂ CH ₂ N(CH ₃) ₂	H	H	F
CH ₂ CH ₂	H	CH ₂ SC(CH ₃) ₃	H	H	F
CH ₂ CH ₂	H	CH ₂ CH ₂ CH ₂ CH ₃	CH ₂ CH ₂ CH ₂ CH ₃	H	F
CH ₂ CH ₂	H	CH ₂ C ₆ H ₅	H	H	H

- 72 -

CH ₂ CH ₂	H	CH ₂ C ₆ H ₅ -p-OH	H	H	H
CH ₂ CH ₂	H	CH ₂ C ₆ H ₅ -p-CN	H	H	H
CH ₂ CH ₂	H	cyclohexyl	H	H	H
CH ₂ CH ₂	H	CH ₂ cyclohexyl	H	H	H
CH ₂ CH ₂	H	CH ₂ CH ₂ CH ₂ NH ₂	H	H	H
CH ₂ CH ₂	H	CH ₂ CH ₂ CH ₂ CH ₂ NH ₂	H	H	H
CH ₂ CH ₂	H	C(CH ₃) ₂ C ₆ H ₅	H	H	H
CH ₂ CH ₂	H	CH(CH ₃) ₂	H	H	H
CH ₂ CH ₂	H	CH ₂ CH(CH ₃) ₂	H	H	H
CH ₂ CH ₂	H	CH(CH ₃) ₂	CH ₃	H	H
CH ₂ CH ₂	H	R ₂ , R ₄ = CH ₂ CH ₂ CH ₂	H	R ₂ , R ₄ = CH ₂ CH ₂ CH ₂	H
CH ₂ CH ₂	H	CH ₂ CH ₂ CH ₂ CH ₂ N(CH ₃) ₂	H	H	H
CH ₂ CH ₂	H	CH ₂ SC(CH ₃) ₃	H	H	H
CH ₂ CH ₂	H	CH ₂ CH ₂ CH ₂ CH ₃	CH ₂ CH ₂ CH ₂ CH ₃	H	H
CH ₂ CH ₂	H	C(CH ₃) ₃	H	H	H
CH ₂ CH ₂	H	CH ₂ C ₆ H ₅	H	H	Cl
CH ₂ CH ₂	H	CH ₂ C ₆ H ₅ -p-OH	H	H	Cl
CH ₂ CH ₂	H	CH ₂ C ₆ H ₅ -p-CN	H	H	Cl
CH ₂ CH ₂	H	cyclohexyl	H	H	Cl
CH ₂ CH ₂	H	CH ₂ cyclohexyl	H	H	Cl
CH ₂ CH ₂	H	CH ₂ CH ₂ CH ₂ NH ₂	H	H	Cl
CH ₂ CH ₂	H	CH ₂ CH ₂ CH ₂ CH ₂ NH ₂	H	H	Cl
CH ₂ CH ₂	H	C(CH ₃) ₂ C ₆ H ₅	H	H	Cl
CH ₂ CH ₂	H	CH(CH ₃) ₂	H	H	Cl
CH ₂ CH ₂	H	CH ₂ CH(CH ₃) ₂	H	H	Cl
CH ₂ CH ₂	H	CH(CH ₃) ₂	CH ₃	H	Cl
CH ₂ CH ₂	H	R ₂ , R ₄ = CH ₂ CH ₂ CH ₂	H	R ₂ , R ₄ = CH ₂ CH ₂ CH ₂	Cl
CH ₂ CH ₂	H	CH ₂ CH ₂ CH ₂ CH ₂ N(CH ₃) ₂	H	H	Cl
CH ₂ CH ₂	H	CH ₂ SC(CH ₃) ₃	H	H	Cl
CH ₂ CH ₂	H	CH ₂ CH ₂ CH ₂ CH ₃	CH ₂ CH ₂ CH ₂ CH ₃	H	Cl
CH ₂ CH ₂	H	C(CH ₃) ₃	H	H	Cl
CH ₂ CH ₂	H	CH ₂ C ₆ H ₅	H	H	CH ₃
CH ₂ CH ₂	H	CH ₂ C ₆ H ₅ -p-OH	H	H	CH ₃
CH ₂ CH ₂	H	CH ₂ C ₆ H ₅ -p-CN	H	H	CH ₃
CH ₂ CH ₂	H	cyclohexyl	H	H	CH ₃
CH ₂ CH ₂	H	CH ₂ cyclohexyl	H	H	CH ₃
CH ₂ CH ₂	H	CH ₂ CH ₂ CH ₂ NH ₂	H	H	CH ₃
CH ₂ CH ₂	H	CH ₂ CH ₂ CH ₂ CH ₂ NH ₂	H	H	CH ₃
CH ₂ CH ₂	H	C(CH ₃) ₂ C ₆ H ₅	H	H	CH ₃
CH ₂ CH ₂	H	CH(CH ₃) ₂	H	H	CH ₃
CH ₂ CH ₂	H	CH ₂ CH(CH ₃) ₂	H	H	CH ₃
CH ₂ CH ₂	H	CH(CH ₃) ₂	CH ₃	H	CH ₃
CH ₂ CH ₂	H	R ₂ , R ₄ = CH ₂ CH ₂ CH ₂	H	R ₂ , R ₄ = CH ₂ CH ₂ CH ₂	CH ₃
CH ₂ CH ₂	H	CH ₂ CH ₂ CH ₂ CH ₂ N(CH ₃) ₂	H	H	CH ₃
CH ₂ CH ₂	H	CH ₂ SC(CH ₃) ₃	H	H	CH ₃
CH ₂ CH ₂	H	CH ₂ CH ₂ CH ₂ CH ₃	CH ₂ CH ₂ CH ₂ CH ₃	H	CH ₃
CH ₂ CH ₂	H	C(CH ₃) ₃	H	H	CH ₃
CH ₂	H	CH ₂ C ₆ H ₅ -p-OH	H	H	F
CH ₂	H	CH ₂ C ₆ H ₅ -p-OH	H	H	F
CH ₂	H	CH ₂ C ₆ H ₅ -p-CN	H	H	F
CH ₂	H	cyclohexyl	H	H	F

- 73 -

CH ₂	H	CH ₂ CH ₂ CH ₂ NH ₂	H	H	F
CH ₂	H	CH ₂ CH(CH ₃) ₂	H	H	F
CH ₂	H	CH(CH ₃) ₂	CH ₃	H	F
CH ₂	H	R ₂ ,R ₄ = CH ₂ CH ₂ CH ₂	H	R ₂ ,R ₄ = CH ₂ CH ₂ CH ₂	F
CH ₂	H	CH ₂ CH ₂ CH ₂ CH ₂ N(CH ₃) ₂	H	H	F
CH ₂	H	CH ₂ SC(CH ₃) ₃	H	H	F
CH ₂	H	CH ₂ CH ₂ CH ₂ CH ₃	CH ₂ CH ₂ CH ₂ CH ₃	H	F
CH ₂	H	CH ₂ C ₆ H ₅	H	H	H
CH ₂	H	CH ₂ C ₆ H ₅ -p-OH	H	H	H
CH ₂	H	CH ₂ C ₆ H ₅ -p-CN	H	H	H
CH ₂	H	cyclohexyl	H	H	H
CH ₂	H	CH ₂ cyclohexyl	H	H	H
CH ₂	H	CH ₂ CH ₂ CH ₂ NH ₂	H	H	H
CH ₂	H	CH ₂ CH ₂ CH ₂ CH ₂ NH ₂	H	H	H
CH ₂	H	C(CH ₃) ₂ C ₆ H ₅	H	H	H
CH ₂	H	CH(CH ₃) ₂	H	H	H
CH ₂	H	CH ₂ CH(CH ₃) ₂	H	H	H
CH ₂	H	CH(CH ₃) ₂	CH ₃	H	H
CH ₂	H	R ₂ ,R ₄ = CH ₂ CH ₂ CH ₂	H	R ₂ ,R ₄ = CH ₂ CH ₂ CH ₂	H
CH ₂	H	CH ₂ CH ₂ CH ₂ CH ₂ N(CH ₃) ₂	H	H	H
CH ₂	H	CH ₂ OH	H	H	H
CH ₂	H	CH ₂ SC(CH ₃) ₃	H	H	H
CH ₂	H	CH ₂ CH ₂ CH ₂ CH ₃	CH ₂ CH ₂ CH ₂ CH ₃	H	H
CH ₂	H	C(CH ₃) ₃	H	H	H

Preparations of starting material for the above examples.

5

***N*}-[(4-{(2*R*,3*R*)-1-(4-fluorophenyl)-3-[(3-nitropyridin-2-yl)dithio]-4-oxoazetidin-2-yl}phenoxy)acetyl]glycyl-3-methyl-*D*-valine**

- 10 To a solution of *tert*-butyl (4-{(2*R*,3*R*)-1-(4-fluorophenyl)-3-[(3-nitropyridin-2-yl)dithio]-4-oxoazetidin-2-yl}phenoxy)acetate (Method 6) (0.250 g, 0.448 mmol) in dichloromethane (5 ml) was added trifluoroacetic acid (1 g). After 2h, full conversion to the corresponding acid was obtained. The reaction mixture was concentrated to give the acid as a yellow solid. To a solution of this acid and *N*-methylmorpholine (0.177 g, 1.755 mmol) in DMF (4 ml) under an atmosphere of nitrogen was added TBTU (0.183 g, 0.570 mmol). After 1h, glycyl-3-methyl-*D*-valine trifluoroacetate salt (Method 10) (0.159 g, 0.526 mmol) was added. The reaction was allowed to stir for 10 minutes after which it was quenched by the addition of water (1ml). Preparative HPLC of the mixture using an eluent of 0-50% CH₃CN in 0.1M NH₄OAc buffer
- 15

followed by freeze drying of pure fractions afforded the desired compound. m/z: 672.6 (M + 1). ¹H NMR [(CD₃)₂SO), 400 MHz] δ 0.88 (s, 9H), 3.80-3.84 (m, 2H), 4.02-4.06 (m, 1H), 4.49-4.67 (m, 3H), 5.21-5.26 (m, 1H), 6.51-7.49 (m, 10H), 7.79-7.81 (m, 1H), 7.95 (dd, 1H), 8.23-8.32 (m, 1H).

5

***N*-({4-[(2*R*,3*R*)-3-{[2-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycine**

10

To a stirred solution of {4-[(2*R*,3*R*)-3-{[2-(1,3-benzodioxol-5-yl)-2-oxoethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetic acid (Method 7) 208 mg, 0.41 mmol) in DCM (16 ml) were added *N*-methylmorpholine (130 μl, 1.18 mmol), *tert*-butyl glycinate hydrochloride (102.3 mg, 0.61 mmol) and TBTU (180.8 mg, 0.56 mmol). The reaction mixture was stirred at ambient temperature overnight. The formation of the intermediate *tert*-butyl *N*-({4-[(2*R*,3*R*)-3-{[2-(1,3-benzodioxol-5-yl)-2-oxoethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycinate confirmed. M/z: 623.88 (M+1) and 621.84 (M-1). The solvent was removed under reduced pressure and the residue was passed through a short silica gel pad and eluted with DCM:EtOAc 8:2. The collected fractions were concentrated under reduced pressure. The crude oil (0.818 mg) was dissolved in DCM (6 ml) and TFA (4 ml) was added and the mixture was stirred for 1 hour. The formation of the ketone of the title compound was confirmed. M/z: 567.74 (M+1) and 565.79 (M-1). The solvent was co-evaporated with toluene under reduced pressure. The residue was dissolved in methanol (8 ml) and sodium borohydride (128.6 mg, 3.40 mmol) and the mixture was stirred for 40 minutes. Ammonium acetate (200 mg) was added and the solvent was removed under reduced pressure. The residue was purified with preparative HPLC on a C8 column, UV 240/260 nm. A gradient from 20 to 50 % MeCN in 0.1M NH₄OAc buffer was used as eluent. The pure fractions were collected and the MeCN was removed under reduced pressure. The remaining water solution was acidified to pH 1 with HCl (1M) and extracted with DCM. The organic phase was passed through a phase separator and concentrated under reduced pressure. The residue was dissolved in MeCN and water. After lyophilisation, the title compound was obtained. H-NMR (400 MHz, DMSO-d₆): 2.78-2.89 (m, 2H), 3.76 (d, 2H), 4.22-4.25 (m, 1H), 4.49 (s, 2H), 4.55-4.64 (m, 1H), 5.01 (d, 0.5H), 5.03 (d, 0.5H), 5.52 (bs, 1H), 5.90-5.94 (m,

2H), 6.70-6.79 (m, 2H), 6.82 (s, 1H), 6.96 (d, 2H), 7.08-7.16 (m, 2H), 7.18-7.24 (m, 2H), 7.34 (d, 2H), 8.34 (t, 1H). M/z: 567.52 (M-1).

(4S)-3-[[4-Methoxybenzyl]thio]acetyl]-4-phenyl-1,3-oxazolidin-2-one

5

[(4-Methoxybenzyl)thio]acetic acid (1.3 g, 6.1 mmol) was dissolved in dry CH₂Cl₂ (40 ml) and given 0°C. N,N'-Dicyclohexylcarbodiimide (DCC, 6.1 g, 6.1 mmol) and 4-(dimethylamino)pyridine (DMAP, 1.6 g, 12.9 mmol) were added and the mixture was stirred for 30 minutes. (S)-(+)-4-Phenyl-2-oxazolidinone (1.0 g, 6.1 mol) was added and the mixture
10 was stirred at room temperature for 24 hours. The mixture was filtrated, concentrated under reduced pressure and purified by flash-chromatography (Hex : EtOAc 8:2 then 1:1). This afforded the title compound.

¹H-NMR (CDCl₃, 200 MHz): δ 3.46-3.59 (m, 3H), 3.74-3.76 (m, 4H), 4.23-4.28 (m, 1H), 4.68 (t, *J* = 8.8 Hz, 1H), 5.38-5.42 (m, 1H), 6.78 (d, *J* = 8.6 Hz, 2H), 7.14 (d, *J* = 8.6 Hz, 2H),
15 7.32-7.40 (m, 5H).

***tert*-Butyl (4-[(1*R*)-1-[(4-fluorophenyl)amino]-2-[(4-methoxybenzyl)thio]-3-oxo-3-[(4*S*)-2-oxo-4-phenyl-1,3-oxazolidin-3-yl]propyl}phenoxy)acetate**

20

TiCl₄ (1M in CH₂Cl₂, 12.6 mL, 12.6 mmol) was added to a solution of tetraisopropyl orthotitanate (1.24 mL, 4.2 mmol) in CH₂Cl₂ (80 mL) held at 0°C under inert atmosphere. The mixture was stirred for 15 minutes, then (4*S*)-3-[[4-methoxybenzyl]thio]acetyl]-4-phenyl-1,3-oxazolidin-2-one (Method 3) (6.0 g, 16.8 mmol) in dry CH₂Cl₂ (60 mL) was added
25 dropwise over 30 minutes and the mixture was stirred for ten minutes. Then *tert*-butyl (4-[(*E*)-[(4-fluorophenyl)imino]methyl]phenoxy)acetate (Method 18) (11.1 g, 33.6 mmol) in dry CH₂Cl₂ (60 mL) was added dropwise over 30 minutes, the mixture was given -40°C and stirred for 20 minutes. Ethyl diisopropyl amine (5.8 mL, 33.6 mmol) in 20 mL CH₂Cl₂ was added dropwise over 20 minutes and the mixture was stirred at -40°C for 90 minutes. The
30 mixture was then given -78°C, added isopropanol (50 mL) and slowly given room temperature over two hours. H₂O (100 mL) was added and the mixture was stirred for 20 minutes at room temperature and then extracted twice with diethyl ether. The combined organic layer was washed with water, dried (MgSO₄) and concentrated under reduced

pressure. The crude product was dissolved in methanol and an off-white precipitate formed. Filtration and drying afforded the title compound.

¹H-NMR (CDCl₃, 200 MHz): δ 1.5 (s, 9H), 3.65 (s, 1H), 3.8 (s, 3H), 4.1 (m, 1H), 4.4-4.6 (m, 4H), 5.0-5.2 (m, 2H), 5.4 (m, 1H), 6.4-6.6 (m, 2H), 6.7-7.4 (m, 15H).

5

***tert*-Butyl (4-((2*R*,3*R*)-1-(4-fluorophenyl)-3-[(4-methoxybenzyl)thio]-4-oxoazetidin-2-yl)phenoxy)acetate**

tert-Butyl (4-((1*R*)-1-[(4-fluorophenyl)amino]-2-[(4-methoxybenzyl)thio]-3-oxo-3-[(4*S*)-2-oxo-4-phenyl-1,3-oxazolidin-3-yl]propyl)phenoxy)acetate (Method 4) (9.3 g, 13.5 mmol) was dissolved in dry toluene (500 mL) and heated to 90°C under inert atmosphere. N,O-Bis(trimethylsilyl)acetamide (BSA, 9.9 mL, 40.6 mmol) was added and the mixture was stirred at 90°C for one hour. The mixture was then given 45°C and tetrabutylammonium fluoride (TBAF, 1 g) was added. The mixture was stirred at 45°C for 24 hours. After cooling, the mixture was concentrated under reduced pressure and purified by flash-chromatography (Hex : EtOAc 6:1 then 5:1 then 4:1). This afforded the title compound.

15

¹H-NMR (CDCl₃, 200 MHz): δ 1.5 (s, 9H), 3.7 (s, 3H), 3.9 (m, 3H), 4.5 (m, 3H), 6.7 (d, 2H), 6.8-7.0 (m, 4H), 7.0-7.2 (m, 6H).

20

***tert*-Butyl (4-((2*R*,3*R*)-1-(4-fluorophenyl)-3-[(3-nitropyridin-2-yl)dithio]-4-oxoazetidin-2-yl)phenoxy)acetate**

tert-Butyl (4-((2*R*,3*R*)-1-(4-fluorophenyl)-3-[(4-methoxybenzyl)thio]-4-oxoazetidin-2-yl)phenoxy)acetate (Method 5) (2.54 g, 4.86 mmol) was dissolved in CH₂Cl₂ (60 mL) and given 0°C under inert atmosphere. 3-Nitro-2-pyridinesulfenyl chloride (1.11 g, 5.82 mmol) was added and the mixture was stirred for two hours at 0°C, the one hour at room temperature. Concentration under reduced pressure and purification by flash-chromatography (Hex : EtOAc 2:1) afforded the title compound.

25

¹H-NMR (CDCl₃, 200 MHz): δ 1.6 (s, 9H), 4.3 (d, 1H), 4.5 (s, 2H), 5.2 (d, 1H), 6.8-7.0 (m, 4H), 7.1-7.3 (m, 4H), 7.4 (m, 1H) 8.5 (d, 1H), 8.9 (d, 1H).

30

{4-[(2*R*,3*R*)-3-[[2-(1,3-Benzodioxol-5-yl)-2-oxoethyl]thio]-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetic acid

tert-Butyl (4-((2*R*,3*R*)-1-(4-fluorophenyl)-3-[(3-nitropyridin-2-yl)dithio]-4-oxoazetidin-2-yl)phenoxy)acetate (Method 6) (0.050 g, 0.090 mmol) was dissolved in acetone (4 ml) at room temperature. Water (0.5 ml) and triphenyl phosphine (0.025 g, 0.095 mmol) were added and the mixture was stirred at room temperature for 30 minutes. The solvent was removed under reduced pressure and the residue was immediately dissolved in DCM (4 ml). 1-(1,3-Benzodioxol-5-yl)-2-bromoethanone (0.055 g, 0.226 mmol) and Et₃N (0.030 ml, 0.272 mmol) were added and the mixture was stirred at room temperature for 18 hours. The reaction mixture was concentrated under reduced pressure and the residue was dissolved in formic acid (4 ml). The solution was stirred at RT for 90 min before the solvent was removed under reduced pressure. The residue was purified by preparative HPLC using a gradient of 20-60% MeCN in a 0.1M ammonium acetate buffer as eluent. Freeze-drying of the pure fractions gave the desired product.

M/z: 510.8. ¹H NMR (DMSO, 400 MHz): δ 4.26 (ABq, 2H), 4.29 (d, 1H), 4.33 (bs, 2H), 5.11 (d, 1H), 6.10-6.15 (m, 2H), 6.79-6.84 (m, 2H), 6.97-7.02 (m, 1H), 7.10-7.32 (m, 6H), 7.38-7.42 (m, 1H), 7.54-7.60 (m, 1H).

20 {4-[(2*R*,3*R*)-3-{[2-(1,3-Benzodioxol-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetic acid

To a solution of {4-[(2*R*,3*R*)-3-{[2-(1,3-Benzodioxol-5-yl)-2-oxoethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetic acid (Method 7) (0.010 g, 0.020 mmol) in methanol (2 ml) was added NaBH₄ (0.010 g, 0.265 mmol). After 15 min the reaction was quenched by the addition of an aqueous solution of hydrochloric acid (1M, 1 ml) and most of the methanol was removed under reduced pressure. The remaining solution was purified by preparative HPLC using a gradient of 20-60% MeCN in a 0.1M ammonium acetate buffer as eluent. Freeze-drying of the pure fractions gave the product.

30 M/z (ES⁻): 510.8. ¹H NMR (DMSO, 500 MHz): δ 2.82-2.94 (m, 2H), 4.27-4.30 (m, 1H), 4.60-4.68 (m, 3H), 5.03-5.08 (m, 1H), 5.56 (bs, 1H), 5.95-5.99 (m, 2H), 6.73-6.96 (m, 5H), 7.13-7.28 (m, 4H), 7.34-7.39 (m, 2H).

Glycyl-3-cyclohexyl-D alanine

N-(*tert*-butoxycarbonyl)glycine (2.0 g, 11.4 mmol) and DIPEA (4.0 g, 31 mmol) were dissolved in methylene chloride (25 ml). TBTU (4.1 g, 12.8 mmol) was added and the mixture was stirred for 15 min at room temperature. 3-cyclohexyl-D-alanine (2.1 g, 12.2 mmol) was added and the reaction mixture was stirred over night at room temperature. The reaction mixture was transferred to a separation funnel and was then extracted with a water/acetic acid solution (100ml 5% acetic acid). The organic layer was separated and evaporated under reduced pressure. The residue was dissolved in formic acid (20 ml) and the mixture was stirred over night at 40 °C. The formic acid was removed under reduced pressure. The residue was washed with water (50 ml) and then stirred in acetone (25 ml) for 1 h at room temperature. The solid material was filtered off and washed with acetone (20 ml). The title compound was obtained.

¹H-NMR, 300 MHz, CD₃COOD): 0.8-1.9 (m, 13H), 3.9-4.1 (m, 2H), 4.55-4.65 (m, 1H).

Glycyl-3-methyl-D-valine trifluoroacetate

To a 30 °C solution of *N*-(*tert*-butoxycarbonyl)glycine (0.450 g, 2.569 mmol) and *N*-methylmorpholine (1.30 g, 12.84 mmol) in CH₂Cl₂ (50 ml) was added TBTU (0.99 g, 3.08 mmol). After 1.5 h, D-*tert*-leucine (0.303 g, 2.31 mmol) was added. After 30 minutes, the reaction was quenched by the addition of water (1 ml). The mixture was concentrated and the residue was purified through preparative HPLC using an eluent of 0-40% CH₃CN in 0.1M NH₄OAc buffer. Pure fractions were collected and concentrated. To the residue were added CH₂Cl₂ (10 ml) and TFA (3 ml). Full conversion to the corresponding aminoacid was obtained after 30 minutes. The reaction mixture was concentrated to give the desired compound. ¹H NMR [(CD₃)₂SO], 400 MHz] □ 0.94 (s, 9H), 3.60-3.67 (m, 2H), 4.16 (d, 1H), 7.90-8.00 (m, 3H), 8.47 (d, 1H).

30 Ethyl {[2-(1,3-benzodioxol-5-yl)-2-oxoethyl]thio}acetate

Ethyl 2-mercaptoacetate (9.68 mL, 88.3 mmol) was added dropwise to a suspension of K₂CO₃ (12.2 g, 88.3 mmol) and 1-(1,3-benzodioxol-5-yl)-2-bromoethanone (21.4 g, 88.3 mmol) in

dry acetone (100 mL). The mixture was stirred at reflux for seven hours, cooled at an icebath and added 200 mL water. Diethyl ether (400 mL) was added and the phases were separated. The aqueous layer was extracted with diethyl ether (200 mL) and the combined organic layers were washed with brine (200 mL), dried (MgSO₄) and concentrated. This afforded the title

5 compound.

¹H-NMR (CDCl₃, 300 MHz): δ 1.2-1.3 (t, 3H), 3.3 (s, 2H), 4.0 (s, 2H), 4.1-4.2 (q, 2H), 6.1 (s, 2H), 6.9 (d, 1H), 7.3 (s, 1H), 7.6 (d, 1H).

Ethyl ({[2-(1,3-benzodioxol-5-yl)-5,5-dimethyl-1,3-dioxan-2-yl]methyl}thio)acetate

10

Ethyl {[2-(1,3-benzodioxol-5-yl)-2-oxoethyl]thio}acetate (Method 11) (15.8 g, 0.056 mol) was dissolved in benzene (500 mL) and 2,2-dimethyl-1,3-propanediol (46.6 g, 0.45 mol) and p-toluene sulfonic acid (cat., 500 mg) were added. The mixture was stirred at reflux in a Dean-Stark apparatus for two hours, given room temperature and concentrated under reduced

15 pressure. The resulting white solid was dissolved in CH₂Cl₂ (500 mL) and washed twice with water (300 mL) and brine (300 mL). The organic layer was dried (MgSO₄) and concentrated under reduced pressure. The crude oil was purified by flash-chromatography (heptane:EtOAc 4:1) to afford the desired product.

20 ¹H-NMR (CDCl₃, 200 MHz): δ 0.6 (s, 3H), 1.2-1.4 (m, 6H), 2.9 (s, 2H), 3.2 (s, 2H), 3.4 (s, 4H), 4.1 (q, 2H), 6.0 (s, 2H), 6.8-7.0 (m, 3H).

(({[2-(1,3-Benzodioxol-5-yl)-5,5-dimethyl-1,3-dioxan-2-yl]methyl}thio)acetic acid

25

Ethyl ({[2-(1,3-benzodioxol-5-yl)-5,5-dimethyl-1,3-dioxan-2-yl]methyl}thio)acetate (Method 12) (14.2 g, 0.039 mol) was dissolved in THF (300 mL) and cooled to 0°C. LiOH (4.87 g, 0.12 mol) in water (100 mL) was added, and the mixture was given room temperature and stirred for 19 hours. The solvents were evaporated, the crude product was added water and

30 extracted with diethyl ether. The aqueous layer was added 1M HCl until pH=3 and extracted twice with CH₂Cl₂. The combined CH₂Cl₂ layers were dried (Na₂SO₄) and concentrated under reduced pressure to afford the desired product.

¹H-NMR (CDCl₃, 300 MHz): δ 0.6 (s, 3H), 1.3 (s, 3H), 3.0 (s, 2H), 3.4 (s, 2H), 3.5 (m, 4H), 6.0 (s, 2H), 6.8-7.0 (m, 3H).

(4S)-3-[(2-(1,3-Benzodioxol-5-yl)-5,5-dimethyl-1,3-dioxan-2-yl)methyl]thio)acetyl]-4-phenyl-1,3-oxazolidin-2-one

((2-(1,3-Benzodioxol-5-yl)-5,5-dimethyl-1,3-dioxan-2-yl)methyl)thio)acetic acid (Method 13) (12.7 g, 37.4 mmol) was dissolved in dry CH₂Cl₂ (150 ml) and given 0°C. N,N'-Dicyclohexylcarbodiimide (DCC, 8.48 g, 37.4 mmol) and 4-(dimethylamino)pyridine (DMAP, 9.13 g, 74.8 mmol) were added and the mixture was stirred at 0°C for 20 minutes. (S)-(+)-4-Phenyl-2-oxazolidinone (6.10 g, 37.4 mmol) was added and the mixture was stirred at room temperature for 16 hours. The mixture was filtrated, concentrated under reduced pressure and purified by flash-chromatography (heptane : EtOAc 2:1). This afforded the title compound.

¹H-NMR (CDCl₃, 200 MHz): δ 0.6 (s, 3H), 1.3 (s, 3H), 2.8 (s, 2H), 3.4 (m, 4H), 3.9 (s, 2H), 4.3 (dd, 1H), 4.7 (t, 1H), 5.4 (dd, 1H), 6.0 (s, 2H), 6.8-7.0 (m, 3H) 7.2-7.5 (m, 6H).

***tert*-Butyl (4-((1*R*,2*R*)-2-((2-(1,3-benzodioxol-5-yl)-5,5-dimethyl-1,3-dioxan-2-yl)methyl)thio)-1-((4-fluorophenyl)amino)-3-oxo-3-((4*S*)-2-oxo-4-phenyl-1,3-oxazolidin-3-yl)propyl)phenoxy)acetate**

Tetraisopropyl orthotitanate (2.74 mL, 9.3 mmol) was added to a solution of TiCl₄ (1M in CH₂Cl₂, 27.8 mL, 27.8 mmol) in CH₂Cl₂ (150 mL) held at 0°C under inert atmosphere. The mixture was stirred for ten minutes, then (4*S*)-3-((2-(1,3-benzodioxol-5-yl)-5,5-dimethyl-1,3-dioxan-2-yl)methyl)thio)acetyl]-4-phenyl-1,3-oxazolidin-2-one (Method 14) (18.0 g, 37.1 mmol) in dry CH₂Cl₂ (200 mL) was added dropwise over 30 minutes and the mixture was stirred for ten minutes at 0°C. Then *tert*-butyl (4-((4-fluorophenyl)imino)methyl)phenoxy)acetate (Method 18) (24.4 g, 74.1 mmol) in dry CH₂Cl₂ (200 mL) was added dropwise over 30 minutes and the mixture was given -30°C and stirred for 20 minutes. Ethyl diisopropyl amine (12.7 mL, 74.1 mmol) was added dropwise over 10 minutes and the mixture was stirred at -30°C for 90 minutes. The mixture was then given -

78°C, added isopropanol (70 mL) and slowly given room temperature over one hour. 10% NH₄Cl (100 mL) was added and the mixture was stirred for 15 minutes at room temperature, added brine (250 mL) and then extracted twice with 600 mL diethyl ether. The combined organic layers were dried (MgSO₄) and concentrated under reduced pressure. Purification by
5 flash-chromatography (heptane : EtOAc 4:1 then 2:1) afforded the desired product.

¹H-NMR (CDCl₃, 200 MHz): δ 0.6 (s, 3H), 1.2 (s, 3H), 1.5 (s, 9H), 2.6-2.8 (m, 2H), 3.2-3.6 (m, 4H), 4.2 (m, 1H), 4.5 (s, 2H), 4.6-4.8 (m, 2H), 5.4 (d, 1H), 5.7 (d, 1H), 6.0 (s, 2H), 6.4 (m, 1H), 6.6-7.5 (m, 15H).

10 MS (CI) m/z: 837.2 (M⁺+Na, 100), 838.3 (50), 839.3 (10), 840.2 (5).

***tert*-Butyl {4-[(2*R*,3*R*)-3-([2-(1,3-benzodioxol-5-yl)-5,5-dimethyl-1,3-dioxan-2-yl]methyl)thio]-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetate**

15

tert-Butyl (4-{(1*R*,2*R*)-2-([2-(1,3-benzodioxol-5-yl)-5,5-dimethyl-1,3-dioxan-2-yl]methyl)thio)-1-[(4-fluorophenyl)amino]-3-oxo-3-[(4*S*)-2-oxo-4-phenyl-1,3-oxazolidin-3-yl]propyl}phenoxy)acetate (Method 15) (22.30 g, 27.4 mmol) was dissolved in dry toluene (800 mL) and heated to 90°C under inert atmosphere. N,O-Bis(trimethylsilyl)acetamide
20 (BSA, 20.1 mL, 82.1 mmol) was added and the mixture was stirred at 90°C for one hour. The mixture was then given 45°C and tetrabutylammonium fluoride trihydrate (TBAF, cat., 1 g) was added and the mixture was stirred at 45°C for 1 hour. The mixture was then concentrated under reduced pressure and purified by flash-chromatography (heptane : EtOAc 5:1). This afforded 10.0 g (56 %) of the title compound as a white solid.

25

¹H-NMR (CDCl₃, 200 MHz): δ 0.6 (s, 3H), 1.2 (s, 3H), 1.5 (s, 9H), 3.0 (q, 2H), 3.3-3.6 (m, 4H), 4.0 (d, 1H), 4.5 (s, 2H), 4.8 (d, 1H), 6.0 (s, 2H), 6.8-7.0 (m, 8H), 7.2-7.3 (m, 3H).

30

{4-[(2*R*,3*R*)-3-([2-(1,3-Benzodioxol-5-yl)-2-oxoethyl]thio)-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetic acid

tert-Butyl {4-[(2*R*,3*R*)-3-({[2-(1,3-benzodioxol-5-yl)-5,5-dimethyl-1,3-dioxan-2-yl]methyl}thio)-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetate (Method 16) (10.0 g, 15.35 mmol) was dissolved in formic acid (100 mL) at room temperature and stirred for two hours. The mixture was concentrated under reduced pressure (temperature < 30°C) and the crude oil was purified by flash-chromatography (heptane:acetone:formic acid 6:4:0.01 and then 5:5:0.01) to afford the title compound.

¹H-NMR (CDCl₃, 200 MHz): δ 4.10 (m, 3H), 4.70 (s, 2H), 4.85 (d, 1H), 6.05 (s, 2H), 6.80-7.00 (m, 5H), 7.20-7.40 (m, 4H), 7.40 (s, 1H), 7.55 (dd, 1H).

MS (CI) *m/z*: 508.0 (M⁺, 100), 509.0 (30), 510.0 (10).

15 ***tert*-butyl (4-[(*E*)-[(4-fluorophenyl)imino]methyl]phenoxy)acetate**

tert-Butyl (4-formylphenoxy)acetate (93.7 g, 0.40 mol) was dissolved in dry toluene (200 mL), added 4-fluoroaniline (38.1 mL, 0.40 mol) and *p*-toluene sulfonic acid (cat, ~1 g). The mixture was refluxed in a Dean-Stark apparatus for 2 hours, cooled at an icebath and a precipitate was formed. The precipitate was filtered, washed with cold heptane and dried to afford the title compound.

¹H-NMR (CDCl₃, 200 MHz): δ 1.6 (s, 9H), 4.8 (s, 2H), 7.0-7.4 (m, 6H), 7.9 (d, 2H), 8.4 (s, 1H).

25 ***tert*-Butyl (4-[(*E*)-[(4-methylphenyl)imino]methyl]phenoxy)acetate**

tert-Butyl (4-formylphenoxy)acetate (5.0 g, 21.2 mmol) was dissolved in dry toluene (100 mL) and *p*-toluidine (2.27 g, 21.2 mmol) was added. The mixture was refluxed in a Dean-Stark apparatus for 18 hours, cooled and concentrated under reduced pressure. Heptane was added and the mixture was concentrated under reduced pressure. This afforded the title compound.

¹H-NMR (CDCl₃, 200 MHz): δ 1.5 (s, 9H), 2.4 (s, 3H), 4.6 (s, 2H), 7.0 (d, 2H), 7.2 (s, 4H), 7.9 (d, 2H), 8.4 (s, 1H).

tert-butyl (4-((1*R*,2*R*)-2-([2-(1,3-benzodioxol-5-yl)-5,5-dimethyl-1,3-dioxan-2-yl]methyl)thio)-1-[(4-methylphenyl)amino]-3-oxo-3-[(4*S*)-2-oxo-4-phenyl-1,3-oxazolidin-5-yl]propyl)phenoxy)acetate

Tetraisopropyl orthotitanate (0.21 mL, 0.72 mmol) was added to a solution of TiCl₄ (1M in CH₂Cl₂, 2.16 mL, 2.16 mmol) in CH₂Cl₂ (40 mL) held at 0°C under inert atmosphere. The mixture was stirred for ten minutes, then (4*S*)-3-([2-(1,3-benzodioxol-5-yl)-5,5-dimethyl-1,3-dioxan-2-yl]methyl)thio)acetyl]-4-phenyl-1,3-oxazolidin-2-one (Method 14) (1.40 g, 2.88 mmol) in dry CH₂Cl₂ (40 mL) was added dropwise over 20 minutes and the mixture was stirred for ten minutes at 0°C. Then *tert*-Butyl (4-((*E*)-[4-methylphenyl]imino)methyl)phenoxy)acetate (Method 19) (2.02 g, 5.77 mmol) in dry CH₂Cl₂ (40 mL) was added dropwise over 20 minutes and the mixture was given -30°C and stirred for 15 minutes. Ethyl diisopropyl amine (0.99 mL, 5.77 mmol) was added dropwise over 10 minutes and the mixture was stirred at -30°C for one hour. The mixture was then given -78°C, added isopropanol (15 mL) and slowly given room temperature over two hours. 10% NH₄Cl (50 mL) was added and the mixture was stirred for 15 minutes at room temperature, added brine (150 mL) and then extracted twice with 300 mL diethyl ether. The combined organic layer was dried (MgSO₄) and concentrated under reduced pressure. Purification by flash-chromatography (heptane : EtOAc 4:1 then 3:1) afforded the title compound.

¹H-NMR (CDCl₃, 200 MHz): δ 0.6 (s, 3H), 1.2 (s, 3H), 1.5 (s, 9H), 2.2 (s, 3H), 2.6-2.8 (m, 2H), 3.2-3.6 (m, 4H), 4.2 (m, 1H), 4.5 (s, 2H), 4.6-4.8 (m, 2H), 5.3 (d, 1H), 5.7 (d, 1H), 6.0 (s, 2H), 6.4 (m, 1H), 6.6-7.5 (m, 15H).

tert-Butyl {4-[(2*R*,3*R*)-3-([2-(1,3-benzodioxol-5-yl)-5,5-dimethyl-1,3-dioxan-2-yl]methyl)thio)-1-(4-methylphenyl)-4-oxoazetidin-2-yl]phenoxy}acetate

tert-Butyl (4-((1*R*,2*R*)-2-([2-(1,3-benzodioxol-5-yl)-5,5-dimethyl-1,3-dioxan-2-yl]methyl)thio)-1-[(4-methylphenyl)amino]-3-oxo-3-[(4*S*)-2-oxo-4-phenyl-1,3-oxazolidin-3-

yl]propyl}phenoxy)acetate (Method 20) (1.70 g, 2.03 mmol) was dissolved in dry toluene (200 mL) and heated to 90°C under inert atmosphere. N,O-Bis(trimethylsilyl)acetamide (BSA, 1.50 mL, 6.10 mmol) was added and the mixture was stirred at 90°C for one hour. The mixture was then given 45°C and tetrabutylammonium fluoride (TBAF, cat., 0.1 g) was added
5 and the mixture was stirred at 45°C for 19 hours. The mixture was then concentrated under reduced pressure and purified by flash-chromatography (heptane : EtOAc 4:1). This afforded the title compound.

¹H-NMR (CDCl₃, 200 MHz): δ 0.6 (s, 3H), 1.2 (s, 3H), 1.5 (s, 9H), 2.1 (s, 3H), 3.0 (d, 2H),
10 3.4 (m, 4H), 4.0 (d, 1H), 4.5 (s, 2H), 4.8 (d, 1H), 6.0 (s, 2H), 6.8-7.4 (m, 11H).

{4-[(2R,3R)-3-{{2-(1,3-Benzodioxol-5-yl)-2-oxoethyl}thio}-1-(4-methylphenyl)-4-oxoazetidin-2-yl]phenoxy}acetic acid

15

tert-Butyl {4-[(2R,3R)-3-({2-(1,3-benzodioxol-5-yl)-5,5-dimethyl-1,3-dioxan-2-yl)methyl}thio)-1-(4-methylphenyl)-4-oxoazetidin-2-yl]phenoxy} acetate (Method 21) (0.21 g, 0.32 mmol) was dissolved in formic acid (10 mL) at room temperature and stirred for 30 minutes. The mixture was concentrated under reduced pressure (temperature < 30°C) and this
20 crude oil was purified by flash-chromatography (heptane:acetone:formic acid 6:4:0.01) to afford the title compound.

¹H-NMR (CDCl₃, 200 MHz): δ 2.25 (s, 3H), 4.05 (d, 1H), 4.10 (d, 2H), 4.60 (s, 2H), 4.85 (d, 1H), 6.05 (s, 2H), 6.80-7.60 (m, 11H).

25 MS (CI) m/z: 504.0 (M⁺, 100), 505.1 (30), 506.0 (10).

β, β -dimethyl-D-phenylalanine trifluoroacetate

30 *N*-(*tert*-butoxycarbonyl)-b,b-dimethyl-D-phenylalanine *tert*-butyl ammonium salt (51.2 mg, 0.14 mmol) was dissolved in DCM (15 ml). Water (10 ml) was added and the mixture was acidified to pH 1 with HCl (1M). The organic phase was washed with water (3x10 ml) and the water phase extracted with DCM (3x10 ml). The solvent was removed under reduced

pressure. The residue was dissolved in DCM (4 ml) and TFA (2.5 ml) was added and the mixture was stirred for 2 hours. The solvent was removed under reduced pressure and the residue was dried under vacuum overnight. The title compound was obtained. M/z: 194.18 (M+1).

5

***tert*-Butyl (4-{(E)-[(4-chlorophenyl)imino]methyl}phenoxy)acetate**

tert-Butyl (4-formylphenoxy)acetate (17.4 g, 73.4 mmol) was dissolved in dry toluene (120 mL) and 4-chloroaniline (9.37 g, 73.4 mmol) was added. The mixture was refluxed in a Dean-Stark apparatus for 20 hours, cooled and concentrated under reduced pressure. Hexane was added and a precipitate formed. This precipitate was filtered, washed twice with cold hexane and dried. This afforded the title compound.

¹H-NMR (CDCl₃, 200 MHz): δ 1.5 (s, 9H), 4.6 (s, 2H), 7.0 (d, 2H), 7.2 (d, 2H), 7.4 (d, 2H), 7.8 (d, 2H), 8.4 (s, 1H).

MS (CI) m/z: 368.0 (M⁺+Na, 100), 369.0 (20), 370.0 (30), 371.0 (10).

***tert*-Butyl (4-{(1R)-1-[(4-chlorophenyl)amino]-2-[(4-methoxybenzyl)thio]-3-oxo-3-[(4S)-2-oxo-4-phenyl-1,3-oxazolidin-3-yl]propyl}phenoxy)acetate**

20

TiCl₄ (1M in CH₂Cl₂, 4.2 mL, 4.2 mmol) was added to a solution of tetraisopropyl orthotitanate (0.4 mL, 1.4 mmol) in CH₂Cl₂ (60 mL) held at 0°C under inert atmosphere. The mixture was stirred for 15 minutes, then (4S)-3-{[(4-methoxybenzyl)thio]acetyl}-4-phenyl-1,3-oxazolidin-2-one (Method 3) (2.0 g, 5.6 mmol) in dry CH₂Cl₂ (60 mL) was added dropwise over 30 minutes and the mixture was stirred for ten minutes. Then *tert*-Butyl (4-{(E)-[(4-chlorophenyl)imino]methyl}phenoxy)acetate (Method 24) (3.9 g, 11.2 mmol) in dry CH₂Cl₂ (60 mL) was added dropwise over 30 minutes, the mixture was given -30°C and stirred for 20 minutes. Ethyl diisopropyl amine (1.9 mL, 11.2 mmol) in 20 mL CH₂Cl₂ was added dropwise over five minutes and the mixture was stirred at -30°C for 60 minutes. The mixture was then given -78°C, added isopropanol (30 mL) and slowly given room temperature over one hour. 10% NH₄Cl (100 mL) was added and the mixture was stirred for 20 minutes at room temperature and then extracted twice with diethyl ether. The combined organic layer was washed with water, dried (MgSO₄) and concentrated under reduced

pressure. Purification by flash-chromatography (Heptane : EtOAc 4:1 then 3:1 then 2:1) afforded the title compound.

MS (CI) m/z: 725.2 ($M^+ + Na$, 100), 727.2 (50), 728.2 (20)

5

***tert*-Butyl (4-((2*R*,3*R*)-1-(4-chlorophenyl)-3-[(4-methoxybenzyl)thio]-4-oxoazetidin-2-yl)phenoxy)acetate**

- 10 *tert*-Butyl (4-((1*R*)-1-[(4-chlorophenyl)amino]-2-[(4-methoxybenzyl)thio]-3-oxo-3-[(4*S*)-2-oxo-4-phenyl-1,3-oxazolidin-3-yl]propyl)phenoxy)acetate (Method 25) (2.3 g, 3.3 mmol) was dissolved in dry toluene (250 mL) and heated to 90°C under inert atmosphere. N,O-Bis(trimethylsilyl)acetamide (BSA, 2.4 mL, 9.8 mmol) was added and the mixture was stirred at 90°C for one hour. The mixture was then given 45°C and tetrabutylammonium fluoride
15 (TBAF, 0.2 g) was added. The mixture was stirred at 45°C for 2 hours. After cooling, the mixture was concentrated under reduced pressure and purified by flash-chromatography (Heptane : EtOAc 4:1). This afforded the title compound.

¹H-NMR (CDCl₃, 200 MHz): δ 1.5 (s, 9H), 3.8 (s, 3H), 3.9 (m, 3H), 4.5 (m, 3H), 6.7 (d, 2H),
20 6.9 (m, 2H), 7.1-7.3 (m, 8H).

***tert*-Butyl (4-((2*R*,3*R*)-1-(4-chlorophenyl)-3-[(3-nitropyridin-2-yl)dithio]-4-oxoazetidin-2-yl)phenoxy)acetate**

- 25 *tert*-Butyl (4-((2*R*,3*R*)-1-(4-chlorophenyl)-3-[(4-methoxybenzyl)thio]-4-oxoazetidin-2-yl)phenoxy)acetate (Method 26) (0.9 g, 1.7 mmol) was dissolved in CH₂Cl₂ (50 mL) and given 0°C under inert atmosphere. 3-Nitro-2-pyridinesulfonyl chloride (0.4 g, 2.0 mmol) was added and the mixture was stirred for 30 minutes at 0°C, then 30 minutes at room temperature. Concentration under reduced pressure and purification by flash-chromatography
30 (Heptane : EtOAc 3:1 then 2:1) afforded the title compound.

4-[(2*R*,3*R*)-3-[[2-(1,3-Benzodioxol-5-yl)-2-oxoethyl]thio]-1-(4-chlorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetic acid

tert-Butyl (4-((2*R*,3*R*)-1-(4-chlorophenyl)-3-[(3-nitropyridin-2-yl)dithio]-4-oxoazetidin-2-yl)phenoxy)acetate (Method 27) (0.70 g, 1.22 mmol) was dissolved in acetone (30 mL) at room temperature, then water (10 mL) and triphenyl phosphine (0.32 g, 1.22 mmol) was added. The mixture was stirred at room temperature for 15 minutes and then concentrated under reduced pressure to afford the crude thiol as a brown oil. This crude thiol was immediately dissolved in CH₂Cl₂ (30 mL) and 1-benzo[1,3]dioxol-5-yl-2-bromo-ethanone (0.59 g, 2.44 mmol) was added, followed by Et₃N (0.34 mL, 2.44 mmol). The mixture was stirred at room temperature for 18 hours, concentrated under reduced pressure and purified by flash-chromatography (Heptane : EtOAc 7:3 and then 2:1). The resulting product (0.90 g) was dissolved in 15 ml formic acid and stirred at room temperature for 3 hours. Concentration under reduced pressure and purification by flash-chromatography afforded the title compound.

¹H-NMR (CDCl₃, 200 MHz): δ 4.1 (s, 3H), 4.7 (d, 2H), 4.9 (s, 1H), 6.1 (s, 2H), 6.8-7.0 (m, 3H), 7.2-7.4 (m, 7H), 7.5 (d, 1H).

MS (CI) *m/z*: 524.0 (M⁺, 100), 525.0 (30), 526.0 (40), 527.0 (10).

20 {4-[(2*R*,3*R*)-3-[[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxoethyl]thio]-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetic acid

To a solution of *tert*-butyl (4-((2*R*,3*R*)-1-(4-fluorophenyl)-3-[(3-nitropyridin-2-yl)dithio]-4-oxoazetidin-2-yl)phenoxy)acetate (0.100 g, 0.179 mmol) in acetone (2 ml) and water (0.5 ml) was added triphenylphosphine (0.047 g, 0.179 mmol). After 30 minutes, the mixture was concentrated. To the residue was added dichloromethane (3 ml) followed by the addition of triethylamine (0.073 g, 0.717 mmol) and 2-bromo-1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethanone (0.115 g, 0.448 mmol). After 30 minutes, full conversion of the thiol had been achieved. The mixture was concentrated and to the residue was added formic acid (2 g) and trifluoroacetic acid (0.2 g). The mixture was allowed to stir at room temperature for 3h. The crude product obtained was purified through preparative HPLC using an eluent of 10-50% CH₃CN in 0.1M NH₄OAc buffer. Freeze drying of pure fractions afforded the desired

compound. ^1H NMR $[(\text{CD}_3)_2\text{SO}]$, 400 MHz] δ 4.21-4.32 (m, 9H), 5.09 (d, 1H), 6.78-7.44 (m, 11H).

5

(R or S)-2-Bromo-1-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-ethanol

10

(R)-2-Methyl-CBS-oxazaborolidine (1M in toluene, 1.95ml, 1.95mmol) was added to a flask containing 20 ml dry THF under $\text{Ar}_2(\text{g})$ at 0°C . $\text{BH}_3\cdot\text{SMe}_2$ (2M in THF, 6.0 ml, 12.0 mmol) was added over 5min. 2-Bromo-1-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-ethanone (4.7 g) was dissolved in 30 ml dry THF, added to a dropping funnel and added to the above solution

15 slowly (ca 4 h) at 0°C . The mixture was stirred over night. The reaction was quenched by addition of 0.4ml MeOH. The mixture was concentrated under reduced pressure, diethyl ether (200 ml) was added and the solution was extracted with 0.5M HCl (pH=1). The aq-phase was extracted with 100 ml diethyl ether and the combined organic phases were washed with ca 2% NaHCO_3 followed by brine. The organic phase was dried with MgSO_4 and concentrated to
20 yield the title compound.

^1H -NMR (CDCl_3 , 400 MHz): δ 3.44-3.62 (m, 2H), 4.26 (s, 4H), 4.78-4.85 (m, 1H), 6.82-6.93 (m, 3H).

25

{4-[(2R,3R)-3-[(R or S)-2-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-2-hydroxy-ethylsulfanyl]-1-(4-fluoro-phenyl)-4-oxo-azetidin-2-yl]-phenoxy}-acetic acid

30 Triphenyl phosphine (0.105 g, 0.400 mmol) was added to a solution of {4-[(2R,3R)-1-(4-fluoro-phenyl)-3-(3-nitro-pyridin-2-yl)disulfanyl]-4-oxo-azetidin-2-yl]-phenoxy}-acetic acid (0.180 g, 0.359 mmol) in acetone/water (4 mL/1 mL) at RT. The mixture was stirred for 15 min before the solvent was removed under reduced pressure. The residue was dissolved in

DMF (5 mL). Triethylamine (0.20 mL, 1.4 mmol) and (R or S)-2-bromo-1-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-ethanol (0.220 g, 0.849 mmol) were added and the solution was stirred at room temperature for 2 h. The reaction was quenched by the addition of NH₄OAc (aq, 0.1 M, 3 mL) and the resulting mixture was purified by preparative HPLC using a gradient of 20-70% MeCN in a 0.1M ammonium acetate buffer as eluent. Freeze-drying of the pure fractions gave of the desired product.

¹H-NMR (DMSO, 400 MHz): δ 2.86 (d, 2H), 4.16-4.23 (m, 6H), 4.26 (d, 1H), 4.53-4.61 (m, 1H), 5.00 (d, 1H), 5.48 (bs, 1H), 6.72-6.84 (m, 5H), 7.10-7.19 (m, 2H), 7.20-7.32 (m, 4H).


Absorption

Absorption of the compounds of formula (I) was tested in a Caco-2 cells model (Gastroenterology 1989, 96, 736):

Compound (I)	Caco value (10 ⁻⁶ cm/sec)
<i>N</i> -({4-[(2 <i>R</i> ,3 <i>R</i>)-3-{[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-methyl-D-valine	0.02
<i>N</i> -({4-[(2 <i>R</i> ,3 <i>R</i>)-3-{[(2 <i>R</i> or <i>S</i>)-2-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-cyclohexyl-D-alanine	0.05

Claims

1. A compound of formula (I):



5

(I)

Wherein:

- 10 X= -CH₂-, - CH₂ CH₂-, - CH₂ CH₂ CH₂-;

R¹= H, C₁₋₆ alkyl, C₃₋₆cycloalkyl or aryl;

R² and R³ is hydrogen, a branched or unbranched C₁₋₆alkyl, C₃₋₆cycloalkyl or aryl; wherein said C₁₋₆alkyl may be optionally substituted by one or more hydroxy, amino, guanidino, carbamoyl, carboxy, C₁₋₆alkoxy, (C₁-C₄alkyl)₃Si, N-(C₁₋₆alkyl)amino, N,N-(C₁₋₆alkyl)₂amino,

- 15 C₁₋₆alkylS(O)_a wherein a is 0-2, C₃₋₆cycloalkyl or aryl; and wherein any aryl group may be optionally substituted by one or two substituents selected from halo, hydroxy, cyano, C₁₋₆alkyl or C₁₋₆alkoxy;

R⁴ is hydrogen, C₁₋₆ alkyl, or arylC₁₋₆ alkyl;

wherein R³ and R² may form a ring with 3-7 carbon atoms and wherein R⁴ and R² may form a

- 20 ring with 2-6 carbon atoms;


R⁵ is selected from hydrogen, halo, nitro, cyano, hydroxy, carboxy, carbamoyl, sulphonamoyl, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, N-(C₁₋₆alkyl)amino, N,N-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, N-(C₁₋₆alkyl)carbamoyl,

N,N-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl,

- 25 N-(C₁₋₆alkyl)sulphonamoyl and N,N-(C₁₋₆alkyl)₂sulphonamoyl; and wherein n is 0, 1, 2 or 3;

or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

2. A compound of formula (I2):



5

(I2)

Wherein:

X = -CH₂-, -CH₂CH₂-, -CH₂CH₂CH₂-;

R¹ = H, C₁₋₆ alkyl, C₃₋₆cycloalkyl or aryl;

10 **R**² and **R**³ is hydrogen, a branched or unbranched C₁₋₆alkyl, C₃₋₆cycloalkyl or aryl; wherein said C₁₋₆alkyl may be optionally substituted by one or more hydroxy, amino, guanidino, carbamoyl, carboxy, C₁₋₆alkoxy, (C₁-C₄ alkyl)₃Si, *N*-(C₁₋₆alkyl)amino,

N,N-(C₁₋₆alkyl)₂amino, C₁₋₆alkylS(O)_a wherein a is 0-2, C₃₋₆cycloalkyl or aryl; and wherein any aryl group may be optionally substituted by one or two substituents selected from halo,

15 hydroxy, cyano, C₁₋₆alkyl or C₁₋₆alkoxy;

R⁴ is hydrogen, C₁₋₆ alkyl, or arylC₁₋₆ alkyl;

wherein **R**³ and **R**² may form a ring with 3-7 carbon atoms and wherein **R**⁴ and **R**² may form a ring with 2-6 carbon atoms;

R⁵ is selected from hydrogen, halo, nitro, cyano, hydroxy, carboxy, carbamoyl, sulphamoyl,

20 C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino,

N,N-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl,

N,N-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl,

N-(C₁₋₆alkyl)sulphamoyl and *N,N*-(C₁₋₆alkyl)₂sulphamoyl; and wherein n is 0, 1, 2 or 3;

or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

25


3. A compound according to claim 1 or 2, wherein X=-CH₂-.
4. A compound according to claim 1 or 2, wherein X=-CH₂ CH₂-.
- 5 5. A compound according to claim 1 or 2, wherein X= -CH₂ CH₂ CH₂-.
6. A compound according to any of the preceding claims, wherein,
 R^1 is hydrogen;
 R^2 and R^3 are hydrogen or a branched or unbranched C₁₋₆alkyl; wherein said C₁₋₆alkyl is
 10 substituted by C₃₋₆cycloalkyl, aryl or amino;
 R^4 is hydrogen.
7. A compound according to any of the preceding claims wherein,
 R^1 is hydrogen;
 15 R^2 and R^3 are hydrogen or a branched or unbranched C₁₋₆alkyl; wherein said C₁₋₆alkyl is
 substituted by C₃₋₆cycloalkyl;
 R^4 is hydrogen.
8. A compound according to claim 7, wherein,
 20 R^2 is hydrogen and R^3 is *tert*-butyl.
9. A compound according to claim 7, wherein,
 R^2 is hydrogen and R^3 is methyl; wherein said methyl is substituted by cyclohexyl .
- 25 10. A compound according to any of the preceding claims, wherein,
 R^5 is selected from chlorine or fluorine.
11. One or more compound choosen from:
 N -({4-[(2*R*,3*R*)-3-{[2-(1,3-Benzodioxol-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-
 30 oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-cyclohexyl-D-alanine;
 N -({4-[(2*R*,3*R*)-3-{[2-(1,3-Benzodioxol-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-
 oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-methyl-D-valine;

N-({4-[(2*R*,3*R*)-3-{[(2*R*)-2-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-methyl-D-valine;

N-({4-[(2*R*,3*R*)-3-{[(2*R*)-2-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-cyclohexyl-D-alanine.

5

12. A compound of the (XVI):



10

Wherein:

X= -CH₂-, -CH₂CH₂-, -CH₂CH₂CH₂-;

15

R¹ is hydrogen, C₁₋₆ alkyl, C₃₋₆cycloalkyl or aryl;

R⁵ is selected from halo, nitro, cyano, hydroxy, carboxy, carbamoyl, sulphamoyl, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a

20 wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl and *N,N*-(C₁₋₆alkyl)₂sulphamoyl; and wherein n is 0, 1, 2 or 3;

R⁷ is an hydroxy group or a C₁₋₄ alkoxy group.

25 13. A method of treating or preventing hyperlipidemic conditions comprising the administration of an effective amount of a compound according to any one of claims 1 to 12 to a mammal in need thereof.

14. A method of treating or preventing atherosclerosis comprising the administration of an effective amount of a compound according to any one of claims 1 to 12 to a mammal in need thereof.

5

15. A method for treating or preventing Alzheimers' disease comprising the administration of an effective amount of a compound according to any one of claims 1 to 12 to a mammal in need thereof.


10 16. A method for treating or preventing cholesterol associated tumors comprising the administration of an effective amount of a compound according to any one of claims 1 to 12 to a mammal in need thereof.

17. A pharmaceutical formulation comprising a compound according to any one of claims 1 to 12 in admixture with pharmaceutically acceptable adjuvants, diluents and/or carriers.

18. A process for preparing a compound of formula (I) or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof which process (wherein variable groups are, unless otherwise specified, as defined in formula (I)) comprising any of the steps:


20

Process 1) reacting a compound of formula (II2):



(II2)

with a compound of formula (III):




(III)

25


wherein L is a displaceable group;

Process 2) reacting an acid of formula (IV2):




(IV2)

5 or an activated derivative thereof; with an amine of formula (V):



(V)


Process 3): reacting an acid of formula (VI2):



(VI2)

10


or an activated derivative thereof, with an amine of formula (VII):



(VII)


Process 4): reducing a compound of formula (VIII2):

- 96 -



(VIII2)


Process 5): reacting a compound of formula (IX2):



(IX2)

5


with a compound of formula (X):



(X)

wherein L is a displaceable group;


10 Process 6): reacting a compound of formula (XI2):



(XI2)


wherein L is a displaceable group; with a compound of formula (XII):

- 97 -



(XII)

Process 7): De-esterifying a compound of formula (XIII2)



(XIII2)

5

wherein the group C(O)OR is an ester group.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE2006/000766

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 13-16
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 13-16 relate to a method of treatment of the human or animal body by surgery or by therapy, as well as diagnostic
.../...
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE2006/000766

Box II.1

methods /Rule 39.1(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE2006/000766

A. CLASSIFICATION OF SUBJECT MATTER

IPC: see extra sheet

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC: C07D, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI DATA, PAJ, CHEM ABS DATA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2004005247 A1 (ASTRAZENECA AB ET AL), 15 January 2004 (15.01.2004), see especially compounds 25, 26 and 30 --	1-12, 17-18
A	WO 9616037 A1 (SCHERING CORPORATION), 30 May 1996 (30.05.1996) --	1-18
A	US 5744467 A (BRIAN A. MCKITTRICK ET AL), 28 April 1998 (28.04.1998) --	1-18

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

20 Sept 2006

Date of mailing of the international search report

03-10-2006

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Eva Johansson/EÖ

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE2006/000766

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>BRIAN A. MCKITTRICK et al, "Synthesis of C3 Heteroatom-Substituted Azetidinones That Display Potent Cholesterol Absorption Inhibitory Activity", J. Med. Chem. 1998, vol. 41, pages 752-759</p> <p>-- -----</p>	1-18

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE2006/000766

International patent classification (IPC)

C07D 405/12 (2006.01)
A61K 31/397 (2006.01)
A61P 25/28 (2006.01)
A61P 3/06 (2006.01)
A61P 9/10 (2006.01)

Download your patent documents at www.prv.se

The cited patent documents can be downloaded at www.prv.se by following the links:

- In English/Searches and advisory services/Cited documents (service in English) or
- e-tjänster/anförda dokument (service in Swedish).

Use the application number as username.

The password is **PQFGMPTPRD**.

Paper copies can be ordered at a cost of 50 SEK per copy from PRV InterPat (telephone number 08-782 28 85).

Cited literature, if any, will be enclosed in paper form.

INTERNATIONAL SEARCH REPORT
Information on patent family members

04/03/2006

International application No.
PCT/SE2006/000766

WO	2004005247	A1	15/01/2004	AU	2003242850	A	00/00/0000
				BR	0312280	A	12/04/2005
				CA	2491789	A	15/01/2004
				CN	1665783	A	07/09/2005
				EP	1521742	A	13/04/2005
				GB	0215579	D	00/00/0000
				IS	7648	A	13/01/2005
				JP	2006501184	T	12/01/2006
				MX	PA04012936	A	16/05/2005
				NO	20050016	A	01/03/2005
				PL	374725	A	31/10/2005
				US	20050239766	A	27/10/2005
				ZA	200410340	A	20/10/2005

WO	9616037	A1	30/05/1996	AT	213726	T	15/03/2002
				AU	698750	B	05/11/1998
				AU	4140196	A	17/06/1996
				BR	9509669	A	28/10/1997
				CA	2205202	A,C	30/05/1996
				CN	1083833	B,C	01/05/2002
				CN	1174548	A	25/02/1998
				CZ	289033	B	17/10/2001
				CZ	9701486	A	12/11/1997
				DE	69525643	D,T	26/09/2002
				DK	792264	T	22/04/2002
				EP	0792264	A,B	03/09/1997
				SE	0792264	T3	
				ES	2169162	T	01/07/2002
				FI	116220	B	14/10/2005
				FI	972099	A	16/05/1997
				HK	1002558	A	00/00/0000
				HU	77088	A	02/03/1998
				JP	2908031	B	21/06/1999
				JP	9512833	T	22/12/1997
				KR	235806	B	01/02/2000
				NO	308468	B	18/09/2000
				NO	972272	A	16/05/1997
				NZ	296720	A	29/03/1999
				PL	184310	B	30/09/2002
				PL	320092	A	15/09/1997
				PT	792264	T	31/07/2002
				RU	2159243	C	20/11/2000
				SK	61697	A	10/12/1997
				SK	283860	B	02/03/2004
				US	5624920	A	29/04/1997
				US	5633246	A	27/05/1997
				US	5744467	A	28/04/1998

INTERNATIONAL SEARCH REPORT
Information on patent family members

04/03/2006

International application No.
PCT/SE2006/000766

US	5744467	A	28/04/1998	AT	213726	T	15/03/2002
				AU	698750	B	05/11/1998
				AU	4140196	A	17/06/1996
				BR	9509669	A	28/10/1997
				CA	2205202	A,C	30/05/1996
				CN	1083833	B,C	01/05/2002
				CN	1174548	A	25/02/1998
				CZ	289033	B	17/10/2001
				CZ	9701486	A	12/11/1997
				DE	69525643	D,T	26/09/2002
				DK	792264	T	22/04/2002
				EP	0792264	A,B	03/09/1997
				SE	0792264	T3	
				ES	2169162	T	01/07/2002
				FI	116220	B	14/10/2005
				FI	972099	A	16/05/1997
				HK	1002558	A	00/00/0000
				HU	77088	A	02/03/1998
				JP	2908031	B	21/06/1999
				JP	9512833	T	22/12/1997
				KR	235806	B	01/02/2000
				NO	308468	B	18/09/2000
				NO	972272	A	16/05/1997
				NZ	296720	A	29/03/1999
				PL	184310	B	30/09/2002
				PL	320092	A	15/09/1997
				PT	792264	T	31/07/2002
				RU	2159243	C	20/11/2000
				SK	61697	A	10/12/1997
				SK	283860	B	02/03/2004
				US	5633246	A	27/05/1997
				WO	9616037	A	30/05/1996
				US	5624920	A	29/04/1997
